|
|
The
HIV/AIDS eNews is published by the British Columbia Persons
With AIDS Society. This publication is a compilation of
various articles collected from various news sources. Opinions
and information expressed are those of the individual authors
and not necessarily those of the Society.
|
|
|
The
7th Annual AccolAIDS Awards Gala is coming soon.
Nominate your hero
today!
The AccolAIDS Awards honour the extraordinary
achievements and dedication of organizations,
businesses, groups and individuals responding to the
AIDS epidemic in British Columbia, and the thousands
of people living in BC who are affected.
For more information on [
Nominating
an AccolAIDS Hero ]
The AccolAIDS Award Gala will be held on April 13,
2008
at the Fairmont Hotel
Vancouver.
|
 |
Simply
Positive:
New
easy-to read treatment information
resources
These
colourful cartoon sheets are designed to explain, as
simply as possible, important HIV treamtent
information. Check all four out
[ here ]or
contact treatment@bcpwa.org to
order your own.
|
AIDS
Walk for Life 2008 Artwork Competition
Winner receives a $1000 honorarium! Are you a Canadian
HIV-positive artist? Want to obtain unprecedented exposure
for you and your artwork? Submit your artwork to be
considered as the centerpiece of the 2008 AIDS Walk for
Life’s creative design! Deadline extended to February 15th,
2008!
[
More Information ]
|
|
Local
& National News
Ottawa Targets Hospital Superbugs
Health agency acts as infection rate soars
February 4, 2008
The federal government is launching a national effort targeting
the superbug methicillin-resistant Staphylococcus aureus in its
bid to reduce the number of hospital-acquired infections that kill
thousands of Canadians each year.
An estimated 220,000 Canadians develop hospital-acquired
infections each year, of which MRSA is one type, according to
Canadian Nosocomial Infection Surveillance Program figures. About
8,000 people die of them annually.
Until now, efforts to reduce the prevalence of superbug infections
have been largely left to individual hospitals, which resulted in
inconsistent policies and outcomes. The annual death toll of
hospital-acquired infections dwarfs that of the 2003 SARS
outbreak, which killed 44 people nationwide.
By targeting MRSA, Howard Njoo of the Public Health Agency of
Canada said it is making patient safety in this country's
hospitals a priority.
Superbugs are of such concern that almost all acute-care Canadian
hospitals and nursing homes now applying for accreditation will
have to provide their rates of MRSA or Clostridium difficile. The
new requirement of the Canadian Council on Health Services
Accreditation, effective as of last month, will compel those
organizations to track the rate of those two types of bacteria as
part of the accreditation process.
And although accreditation is voluntary, 99 per cent of Canada's
acute-care hospitals participate, as do many nursing homes, some
community health centres, home-care organizations and other
health-care facilities.
"We recognize that both in the community and in the health-care
setting, trying to decrease the transmission of infections is very
important," Dr. Njoo, director-general of the agency's Centre for
Communicable Diseases and Infection Control, said.
Hand washing and appropriate use of antibiotics are two measures
that help reduce various forms of hospital-acquired infections,
including MRSA, Dr. Njoo said.
While hand hygiene is a crucial and obvious step to reducing
infections, prodding those who provide care to scrub up has been
maddeningly difficult: only 40 per cent of Canadian health-care
workers properly wash their hands.
Other measures proven to help reduce MRSA include screening
patients for the superbug upon admission to hospital, isolating
hospital patients who have it, proper cleaning of hospital rooms,
and ensuring hospital visitors and health-care workers who come
into contact with those who have MRSA don gloves, gowns and masks.
The federal effort - the largest national effort to date - comes
after it said in September that it would develop a plan by January
on how to reduce the staggering number of infections occurring in
the nation's hospitals. At the time, it was considering three
superbugs: MRSA, vancoymycin-resistant enterococci and C.
difficile. In the end, MRSA was selected, in part, because it is
highly responsive to proper hand hygiene.
Phil Hassen, chief executive officer of the Canadian Patient
Safety Institute, said MRSA is causing a lot of grief in Canadian
hospitals, adding that "this is a safety issue; this is about
preventing harm to people."
The federal government has not yet set a target on how many MRSA
infections it would like to reduce. Joanne Laalo, past president
of the Community and Hospital Infection Control Association of
Canada, the group co-leading the superbug initiative with the
government, stressed that a figure still has to be determined, but
a "reduction by 50 per cent would be wonderful."
MRSA can hide inside a nostril, on a hand or in soiled clothing.
Symptoms can vary from a blotch of reddened skin treatable with a
topical antibiotic to a merciless attack that causes blood
poisoning, decayed lungs, pneumonia and infected heart valves.
The superbug has made significant inroads in Canada, where the
rate of those colonized and infected over the past decade has
increased tenfold. Some of the highest rates have been noted in
Quebec and Ontario, according to the Canadian Nosocomial Infection
Surveillance Program study, which looked at MRSA in 38 hospitals
in nine provinces.
Ontario, for example, is something of an MRSA hot spot: 13,458
patients were found to be colonized or infected with it in 2006,
the highest number the province has ever recorded, according to
the most recent figures from Ontario's Quality Management Program
- Laboratory Services.
The scourge of hospital-acquired infections have been the subject
of marketing campaigns, buttons and posters, most of them aimed at
encouraging health-care workers, patients and visitors to
hospitals to wash their hands.
MRSA
What is MRSA? Methicillin-resistant Staphylococcus aureus is a
bacterial infection resistant to the antibiotic methicillin.
Who is at risk? Hospital patients, the elderly, the very ill and
frequent or long-term users of antibiotics run a greater risk of
acquiring it.
How is MRSA spread? It is usually spread through hand contact. The
hands of health-care workers can become contaminated by contact
with patients, or the bug may cling to surfaces in hospitals and
medical devices.
What are the symptoms? MRSA generally starts as small red bumps
that resemble pimples, boils or spider bites. These can quickly
turn into deep, painful abscesses that require surgical draining.
Sometimes the bacteria remain confined to the skin but they can
also burrow deep into the body, causing potentially
life-threatening infections in bones, joints, surgical wounds, the
bloodstream, heart valves and lungs.Other superbugs
Vancomycin-resistant enterococci: Enterococci are bacteria that
live in the bowels of most people. VRE is a strain that has
developed resistance to many commonly used antibiotics,
specifically vancomycin.
C. difficile: Clostridium difficile is a bacterium that causes
severe diarrhea.
By Lisa Priest, Toronto Globe and Mail
|
|
Conquering AIDS — If We Have A HAART
February 7, 2008

Dr. Julio Montaner: more aggressive
AIDS treatment needed for those in helpless situations.
photo by Brian Smith
One of the world’s leading researchers in HIV/AIDS, Dr. Julio
Montaner, believes it is possible to completely eliminate the
transmission of HIV in Canada, starting in British Columbia.
"We have come a long way in two decades of treating HIV/AIDS,"
says Montaner, Director of the BC Centre for Excellence in
HIV/AIDS. "I really believe by expanding HAART (highly active
anti-retroviral therapy), a therapy proven to work, we can finally
control this epidemic."
There are 12,000 people in British Columbia who are HIV positive.
The B.C. Centre for Excellence in HIV/AIDS estimates that 2,000
are not receiving treatment even though most have access to free
therapy.
HAART treats HIV with a combination of drugs (anti-retrovirals)
that blocks HIV replication at different stages of its life cycle.
As a result, HAART dramatically reduces the amount of HIV in the
blood, known as viral load, and this in turn helps to decrease the
risk of HIV transmission.
"We have proven that among those who engage in care, 90 per cent
show a vast improvement and transmission almost disappears," says
Montaner. "But this benefit is restricted to those who initiate
and adhere to HAART treatment."
The benefits of HAART are major and long lasting – life expectancy
increases and quality of life improves. Further, transmission is
greatly reduced. This means that HIV-infected women can give birth
without transmitting the virus to their babies, as long as they
are on HAART.
"The reality for the more vulnerable members of our community is
that seeking treatment for HIV does not rank high enough to make
it a priority," says Montaner. "This creates completely
unnecessary pain and suffering for people and generates futile
health care expenses."
Most Canadians, if given a HIV-positive verdict, would seek
treatment without delay. This is not the case, however, for many
people who are homeless, mentally ill, substance abusers or all of
the above.
Montaner believes that it’s possible to improve the situation. He
believes that it requires rethinking the current passive approach
to treatment and creating a more aggressive method of providing
care for HIV sufferers in helpless situations. Montaner calls this
approach "seek and treat."
"It is not unlike what we did for tuberculosis in the past," says
Montaner. "We need to go out there, find the cases, and engage
them in comprehensive education, prevention and care programs. We
need a dynamic outreach program that will allow us to find,
through trial and error, effective ways to engage these hard to
reach populations in care. Only then we will be able to stop HIV
in BC."
As Professor of Medicine and Chair of the AIDS Research Division
at UBC and also President-Elect of the International AIDS Society,
Dr. Montaner has worked on treating HIV/AIDS since 1981.
He was the lead investigator of a seminal clinical trial that
demonstrated that non-nucleoside reverse transcriptase inhibitor
(NNRTI) – based HAART could render HIV plasma levels undetectable
and lead to full remission of the disease. Montaner unveiled this
groundbreaking research at the International AIDS Conference held
in Vancouver in 1996.
"Clearly HIV is readily preventable," says Montaner. Still,
HIV/AIDS is ranked fourth on the Top 20 Causes of Death Worldwide
list created by the World Health Organization. Traditional
prevention strategies (including safer sex, harm reduction, etc)
are the number one priority. But when prevention fails, treatment
can be lifesaving. HAART treatment of those in medical need is the
next priority.
"When HAART was introduced as a treatment, the incidence of HIV
was reduced by 50 per cent. But since 1998 these figures have
reached a plateau," explains Montaner. "When you put all the facts
together a new model for prevention and treatment is required."
By Julie-Ann Backhouse,
www.UBC.ca
|
AIDS Advocates Call For Support As Epidemic Grows In Aboriginal
Communities
February 8, 2008
As the number of aboriginal people living with HIV and AIDS in
Canada grows, efforts to address the situation should consider the
social factors, such as poverty, behind the epidemic, advocates
say.
But for much-needed progress to be made, the stigma and
discrimination borne by aboriginal people with AIDS must end,
according to the Canadian Aboriginal AIDS Network. That’s why the
network is calling on First Nations, Métis, and Inuit leaders
ahead of Valentine’s Day, and asking them to speak out on the
issue in public.
"A lot of us take it for granted. If we’re healthy and living with
friends and family and loved ones around us, we think that
everything’s all right in the world," Kevin Barlow, the network’s
executive director, told the Georgia Straight by phone from
Ottawa. "In reality a lot of aboriginal people who are living with
HIV and AIDS talk about the isolation and the rejection they
experience."
Hearing leaders denounce discrimination and then endorse AIDS
prevention, harm-reduction, and treatment programs, he said, will
help create more supportive environments in aboriginal communities
and encourage those at risk of or living with human
immunodeficiency virus or acquired immune deficiency syndrome to
get tested or seek assistance.
"When the awareness level is low, then you have higher levels of
stigma and discrimination," Barlow said. "When you can inform and
educate people, then you bring the stigma and discrimination
levels down a bit, because people are more informed and they’re
not afraid."
Statistics show aboriginal people—who compose 3.8 percent of
Canada’s population, according to the 2006 census—are
overrepresented among cases of HIV and AIDS in Canada, and the
percentages continue to rise.
According to statistics published by the Public Health Agency of
Canada, aboriginal persons made up 3.1 percent of reported AIDS
cases with information on ethnicity from 1979 to 2003, and 23.4
percent of positive HIV-test reports from 1998 to 2003. In 2003,
13.4 percent of reported AIDS cases involved aboriginal persons,
up from 1.2 percent before 1993. Aboriginal persons composed 25.3
percent of positive HIV-test reports in 2003, up from 18.8 percent
in 1998.
Women and youth are also disproportionately represented among new
infections in the aboriginal population, compared to the
non-aboriginal population.
"Infection rates are far worse here amongst aboriginal people than
they are among some Third World developing countries," Shawn
Atleo, regional chief of the British Columbia Assembly of First
Nations, told the Straight. "This should be a general public
concern, not just an aboriginal-health issue."
Atleo said he’s willing to speak publicly to fight the stigma and
discrimination that still surround AIDS and to support the work of
people in the field.
"This is very personal, I think, for everyone in our community.
You don’t have to go far," he said. "I lost one of my childhood
friends to the disease, from Ahousaht, west coast of Vancouver
Island—not on the Downtown Eastside. This is in our communities
everywhere.
Ken Clement, president of the Canadian Aboriginal AIDS Network and
executive director of the Vancouver-based Healing Our Spirit BC
Aboriginal HIV/AIDS Society, said financial, human, and technical
resources are needed in communities across the province to support
aboriginal people living with the disease. Indeed, he said, the
lack of resources in rural communities can lead people with AIDS
to seek out services in Vancouver.
"If we don’t have those resources I talked about, it’s almost
pointless to speak of our future as a nation if we don’t have the
people," Clement said. "It’s kind of ironical that we talk about
treaty process, but if we have our communities infected and
affected by HIV and other health issues, then it seems to be a
lost cause."
Both Barlow and Clement maintained social factors—such as poverty,
lack of education and housing, foster care, and residential-school
wounds—are driving the AIDS epidemic in aboriginal communities.
"When people are below poverty levels and they can’t get gainful
employment and they’re struggling with mental-health challenges or
these childhood wounds that come from things that they have no
control over, it creates a very different dynamic for people,"
Barlow said.
Dirty needles are responsible for most new HIV infections among
aboriginal people, he noted, adding that means there is much
harm-reduction work to be done.
A study by the B.C. Centre for Excellence in HIV/AIDS, to be
published in the March issue of the American Journal of Public
Health, found aboriginal people in Vancouver who inject drugs are
much more likely to have or to be infected with HIV than
non-aboriginal injection-drug users.
Entering the study period, 25.1 percent of aboriginal participants
were HIV-positive, compared to 16 percent of non-aboriginal
subjects. Four years later, 18.5 percent of aboriginal
participants reported new HIV infections, while only 9.5 percent
of non-aboriginal persons did.
"Our findings demand a culturally appropriate and evidence-based
response to the HIV epidemic among Aboriginal injection drug
users," the study’s authors wrote, according to a draft.
By Stephen Hui ,
http://www.straight.com
|
|
Fair Play Or Morality Play?
February 9, 2008
London, Ontario - Barry Mann has been HIV-positive for 19 years
and practises safe sex.
He learned to take precautions after watching many friends die of
AIDS in the 1980s.
Now, at 53, he's scared -- not of infecting his sexual partners
with the virus that causes AIDS, but of being accused of infecting
them -- and going to jail.
"To date, I haven't had somebody who's out to get me," he says.
A recent criminal case in London -- one of four HIV-related cases
before the courts here and one in St. Thomas -- has left Mann with
an uneasy feeling the criminal courts are judging HIV-related
cases on the basis of morality, not public protection.
Ryan Handy, 25, a young gay man with mental illness, was convicted
last month of aggravated sexual assault. He testified that at one
time he believed he had sweated out his HIV and was the Messiah.
After two unprotected sexual encounters with a 53-year-old man he
met in an Internet chat room, Handy testified, he had a moment of
clarity, realized he had the virus and immediately contacted the
man and told him he was HIV-positive. His lack of disclosure of
his HIV status required by law could send Handy to prison when
he's sentenced next month.
There is a debate brewing -- and an opinion in the gay community
-- that the victim in the case, who has remained virus-free,
should have taken care of his own sexual health while engaging in
high-risk sexual behaviour and not be accusing a young, vulnerable
man of a criminal act.
Mann says the courts should stay out of people's bedrooms when it
comes to disclosing HIV.
"It should not be tying up the courts," he says. "It's a health
issue, not a criminal issue."
Breakthroughs in treatment have allowed Mann and many other
HIV-positive people to live with the virus for decades. He's still
legally obligated to tell his sexual partners he has the virus,
something he admits doesn't always happen because he uses
protection.
"I am constantly floored by how many people are willing to have
sex with me without taking precautions. I'm the one who has to
stop them," he says. "Society is still very nonchalant about
this."
It's been 15 years since the death of Charles Ssenyonga, a man
with a virulent strain of AIDS who was being tried for knowingly
spreading the virus to several women -- some of whom died -- in
London. He died just weeks before Superior Court Justice Dougald
McDermid was to deliver a decision.
Half a generation later, there are suggestions it's time for HIV
to be taken out of the Criminal Code.
There have only been 29 HIV-related cases in Canada and six are
before the courts. It appears the majority on trial now are in the
London area. All the current London cases involve men -- two
straight and two gay -- said not to have disclosed their HIV
status to sexual partners.
In the cases of people maliciously spreading the virus, there's a
unified opinion inside and outside the criminal justice system
those cases need to be tried criminally.
But in the Handy case, and in the Mark Hinton case that was
dismissed this week, the facts involved allegations of consensual
sex between people engaged in high risk activities. (Hinton, 41,
who has been HIV-positive for 22 years, faced a charge of
attempted aggravated sexual assault. A judge dismissed the
charge).
Those cases, some activists say, could have best been handled by
public health -- not the criminal justice system that they say
seems to judge morality and not promote public protection.
"If you take the HIV out of there, it's still a crime," says Peter
Hayes, executive director of the AIDS Committee of London, about
HIV cases involving sexual assault and intentional spread of the
disease.
But, he says, "when we make it about HIV-only, the law can be
misinterpreted, or situations are not being addressed in the best
interests of public health."
Hayes says cases like Handy's and others go to the most intimate
piece of a relationship and solidify the stigma attached to
disease that has gone from a death sentence to an often
controllable condition.
Prosecution of such cases leaves the community with a false sense
of security, he says. The reality, he says, is that the vast
majority of HIV-positive people disclose their status not just to
their partners, but to family, employers, doctors and anyone they
believe could be at risk.
The majority of new transmissions are in the straight community
and come from people who haven't been tested.
Brian Lester, director of prevention for the agency, says the best
strategy to stop the transmission of the virus is to encourage
testing and help people make informed decisions about their
results. But criminalization "challenges that, he says.
"People don't want to deal with what could be a reality in their
life," he says, and won't get the test. "A fully informed
individual making a choice not to use a condom is putting
themselves at risk."
Hayes says he's concerned there's not enough education in, and
outside of, the criminal justice system about the virus and the
disease.
He points to a 2003 study across Canada that showed people were
less informed about HIV and AIDS than ever, with beliefs that only
gay men and drug users and people living in Africa were at risk.
"Issues surrounding sex and drugs are being talked in a way that's
not about health but more about morality," he says.
Lester says the health system has the tools to handle the cases.
Already, public health can issue orders that outline rules an
HIV-positive person must follow, such as using condoms in all
sexual encounters and not sharing needles. It also has the power
to detain people, Lester says.
He adds the justice system adds to the stigma when prosecuting
these cases as aggravated sexual assaults.
"I don't understand the term sexual assault in consensual sex," he
says.
Even the failure to disclose during pillow talk needs to be
prosecuted, some in legal circles say.
A London lawyer who successfully defended Hinton agrees HIV cases
should be judged in criminal courts.
"It should absolutely be an offence," says Ron Ellis. "Because you
can't consent to having sexual relations with someone if the act
is so manifestly different than what you expected it was going to
be.
"HIV changes the very nature and character of the sex you are
consenting to such a degree."
HIV still remains potentially life-threatening, he says, and
although not necessarily a death sentence, it requires a lifetime
of treatment and medications. It restricts freedoms and choice of
sexual partners.
"It's got to be worth something," Ellis says.
If Hinton had been found guilty, Ellis notes, he would have faced
a prison sentence of three to six years.
"I think its a crime to put somebody at risk," Ellis says. "The
law is you've got to disclose and it's a good law. It's there for
the health and safety of the community."
Dr. Bryna Warshawsky, associate medical officer of health for the
Middlesex-London Health Unit, says the spread of the virus is
"certainly a health issue," and adds it's "very rare and unusual
for people with HIV not to be responsible."
The Ryan Handy case has become a rallying point for some in the
gay community -- a group of supporters was with him at his
sentencing hearing last month.
Handy can be seen in a three-part interview on the Xtra magazine
website denouncing what he calls unfair treatment by the criminal
courts.
An editorial by managing editor Matt Mills in the gay magazine
criticizing the victim in December prompted the victim in the
Handy case to not submit a victim impact statement.
Mills says he thinks "it's really important that folks who are in
the position he is in have the opportunity to tell their stories."
He says his publication believes some men, particularly gay men,
get "the short end of the stick on this legislation and these
sentencing guidelines.
"We believe the criminal justice system is singularly unqualified
and ill-equipped to handle this issue."
The Supreme Court of Canada, Mills says, in its decision that
HIV-positive people have a duty to disclose their illness before
having unprotected sex, "has put us in a position we are at each
other's throat and suspicious of each other when it is a public
health matter."
Mann, who also recently completed treatment for Hepatitis C,
agrees.
"Nobody forced their pants down. Nobody forced them to have sex.
Everybody's responsibility is to protect themselves."
He fears that whether he discloses his health status or not in the
bedroom becomes hearsay in a courtroom.
"I can disclose to somebody and they can turn around and say I
didn't disclose," he says, adding he fears the issue could evolve
into civil cases in which former lovers are pitted against each
other.
"We're already dealing with living with this disease and the
stigma attached. We don't need this on top of it."
HIV And The Law
The Supreme Court of Canada ruled in 1998 that:
- HIV-positive people must disclose their status to sexual
partners before having sex without a condom or sharing sex toys.
- They must tell people with whom they share drug equipment before
sharing the equipment.
- Non-disclosure could lead to an order by a local public health
unit that would outline rules that must be followed and could
include using a condom in all sexual encounters or no sharing of
needles.
- Criminal Code charges can be laid by a sexual- or needle-sharing
partner. The charges range from common nuisance to aggravated
sexual assault. Charges can be laid even if the partner is not
infected.
Cases Before The Courts
- Edward Kelly, 31, was charged with aggravated sexual assault in
May 2006, after a woman told police she had sex with a man who
didn't tell her he was HIV-positive. He is next in Superior Court
on Feb. 12.
- Tendai Mazambani, 33, was charged with four counts of aggravated
sexual assault in October 2006. He is expected to set a date for
an Ontario Court preliminary hearing.
- The case against Mark Hinton, 41, was dismissed this week after
his complainant admitted HIV status was not a concern to him
before engaging in "moderately high risk" sexual activities.
Hinton, who didn't get the chance to testify, maintained he never
had sex with the man.
- Ryan Handy, 25, a gay man who testified he is mentally ill and
believed he sweated out his HIV, is to be sentenced for aggravated
sexual assault March 27.
- Owen Antoine, 41, of Aylmer was convicted by a jury in St.
Thomas this month of four charges, including aggravated sexual
assault and criminal negligence causing bodily harm. Antoine was
diagnosed HIV-positive in December 2004. The victim, a 29-year-old
woman, testified she was at a bar with Antoine in April 2006 and
has no memory after she drank a shooter he said he took to her.
She woke up hours later in bed with him and he told her they had
unprotected sex. She has since tested positive for HIV. Antoine
did not tell her he had the virus.
By Jane Sims,
http://lfpress.ca
|
|
Liberal Leader Dion Indicates Vancouver Safe Injection Site Is OK
February 8, 2008
Vancouver - The Liberal party has no intention of advocating the
legalization of cannabis but leader Stephane Dion made it clear
Friday that under a Liberal government, other Canadian cities
could see safe injection sites like the one in Vancouver.
Dion, whose party could be embroiled in an election campaign this
spring, took about 20 questions at a "town hall meeting" at the
University of British Columbia.
The questions were wide-ranging and included the Liberal party's
position on Afghanistan, the economy, climate change - and
marijuana.
"It's not something we will campaign on in the next election,"
Dion said candidly. "But we need to have an approach about drugs
that is more effective than the one the government has to date."
Without being asked about it, he told the crowd of about 150
students that Canada's only safe injection site - known as Insite
and situated in the Downtown Eastside - "is something in which we
believe.
"I think the current government has an ideological approach about
that," Dion told the gathering that was co-ordinated by the Young
Liberals of UBC.
"If the science is telling you that an initiative like that is
saving lives, we need to continue it."
The Harper government has said that the city's safe injection site
can remain open until June.
Health Canada announced in October it would extend the exemption
from Canada's drug laws that allows Insite to operate. The
exemption was set to run out at the end of the year.
The site provides a place for addicts to safely inject themselves
with their own heroin under the supervision of medical staff.
A spokeswoman for Health Canada said the exemption will allow
further research.
Dion added that a Liberal government would investigate if there
are other communities in Canada "willing to address the problem
this way."
Another student suggested that Canada often kowtows to the U.S. on
many issues and wanted to know how Dion would deal with the U.S.
administration.
"If you get into power, how are you going to handle the way Canada
kind of lies down when they want us to do something but then when
we want them to do something they kind of slough us off, right?"
the student asked.
"For us Canadians, the United States is a friend," said Dion.
"It is an ally but it is not a model," he said to loud applause.
"This difference between a friend and a model is not well
understood by the current prime minister and it will be by me."
He also told the students that Canada must have its "economic
sovereignty protected."
But as a trading nation with the U.S., he said Canada's "balance
of trade is very advantageous for Canada.
"Our trade with the U.S. must be effective but it must be open as
well because we are making a lot of money trading with them.
The Canadian Press
|
International
News
|
House GOP Opposes AIDS Program Changes
February 8, 2008
Washington - House Republican leader John Boehner and other
Republicans warn that a successful program to combat AIDS in
Africa would be in jeopardy if Democrats move ahead with plans to
make changes.
Boehner, R-Ohio, said the Democratic proposal to renew the
five-year, $15 billion anti-AIDS effort "will undermine this
valuable program as we know it, placing at risk the work it does
on behalf of millions."
In what is shaping up to be a political and ideological showdown,
House Foreign Affairs Committee Chairman Tom Lantos, D-Calif.,
replied that his Democratic proposal reaffirmed the compromise he
worked out with the late Rep. Henry Hyde, R-Ill., in 2003. It is a
shame, he said, that the GOP minority is "failing to honor this
spirit of compromise and is willing to endanger a valuable U.S.
foreign policy program addressing one of the most serious health
care challenges that humanity faces today."
The program expires this year and President Bush, who travels to
Africa this month, has urged Congress to double funding to $30
billion over the next five years. The President's Emergency Plan
for AIDS Relief is now treating 1.4 million people, with the focus
on 15 mostly sub-Saharan African nations.
Democrats, backed by AIDS groups, say that's still not enough to
cope with the continuing HIV/AIDS crisis, and Lantos' committee
next Thursday is to vote on a bill approving $50 billion in funds
and making several changes that have enraged social conservatives.
The Lantos bill would eliminate a provision in the 2003 bill
requiring that one-third of all prevention spending go to
abstinence programs. That amounts to about 7 percent of all
spending. Critics say that while they don't oppose abstinence
programs, inflexible funding requirements are counterproductive.
It also would remove a provision stating that all groups receiving
money under the program must sign a pledge confirming that they do
not support the legalization of prostitution or sex trafficking.
The groups still may provide condoms or condom information to
prostitutes. The provision, said its author, Rep. Chris Smith,
R-N.J., was designed to "ensure that pimps and brothel owners
don't become U.S. government partners."
Democrats said studies have shown that some groups will not or
cannot make the pledge because of concerns it will alienate women
they are trying to reach. Other groups say legalized and
controlled prostitution could help slow the spread of HIV
infection.
Third, Republicans claimed that the Democratic-written bill undoes
carefully crafted rules that allow money to go to family planning
groups for AIDS work as long as no money is spent on abortions.
That change, Rep. Mike Pence, R-Ind., said at a news conference
including anti-abortion groups, "would transform the program into
a mega-funding pool for organizations with an abortion promotion
agenda."
Lantos said the administration has endorsed a link between family
planning and HIV/AIDS programs, and that his bill clarifies that
additional contraceptive services may be provided under the law as
long as these services are focused on stopping the transmission of
HIV/AIDS.
His spokesman, Lynne Weil, said it is clear that funds are not
available for abortion and it strengthens the "conscience clause"
that allows faith-based groups to opt out of any program to which
they have a moral objection.
By The Associated Press, www.365Gay.com
|
|
Alleged Rape Victim Is HIV Positive
February 6, 2008
A court at the Old Bailey has been told that a 26-year-old man who
accused a BBC Radio 4 reporter of raping him is HIV positive.
Nigel Wrench, 47, was open about his status and had made a
documentary, Aids and Me about his experiences living with HIV and
a later diagnosis of AIDS.
He is accused of drugging and sexually assaulting the 26-year-old
after inviting him back to his flat in north London after meeting
him at a New Years party.
Mr Wrench's defence barrister, Sarah Forshaw QC, told the court
that the alleged victim did not mention his HIV status.
Constance Briscoe for the Crown Prosecution Service had earlier
told the court:
"In order to get his way with the victim, he drugged him and he
raped him and he sexually assaulted him.
The jury were told that he suffered from "flashes of darkness" and
"periods of blackness," before finding himself naked on the Mr
Wrench's bed as the radio reporter put a pill into his mouth.
Mr Wrench faces accusations of rape, sexual assault, together with
administering the sleeping tablet, Temazepam, with the intention
of overpowering his victim in order to have sexual intercourse on
the 1st January 2007.
He denies all charges. The trial continues.
PinkNews.co.uk
|
|
HIV Infections Up 20% In Sweden
February 6, 2008
500 people were newly diagnosed as HIV positive in Sweden in 2007
according to data published by the Swedish Institute for
Infectious Disease Control (SMI).
That number represents a rise of 20% on 2006.
There has been a 70% rise in the number of people infected within
Sweden, though the majority of new HIV patients still come into
contact with the virus abroad.
"We have especially seen an increase in the number of new
infections among men who have sex with men and needle-users," SMI
statistician Malin Arneborn told AFP.
MSM infections rose from 50 cases in 2006 to 80 in 2007.
"Interest in HIV/AIDS has gradually declined as people have become
more accustomed to the threat," Claes Herlitz, an expert in
Swedish attitudes to HIV, told AFP.
"They've seen that HIV hasn't spread as quickly as we thought it
would in the late 80s, and there are new medicines making it more
difficult to get AIDS. Fewer people are dying."
In the UK the Health Protection Agency revealed in November that
the number of gay and bisexual men diagnosed with HIV in the UK is
at its highest rate since the start of the epidemic.
2,700 gay and bisexual men were newly diagnosed last year, the
highest number ever.
Across the UK 1 in 20 gay and bisexual men are now living with HIV
and estimates suggest this figure is as high as 1 in 10 in London.
Furthermore, nearly half (47 per cent) of HIV infected gay men who
visit a sexual health clinic leave without being tested for HIV.
Overall diagnoses in the UK remain high.
7,800 people were diagnosed last year, and the numbers living with
HIV in the UK were 73,000 by the end of 2006.
One in three people do not know they are infected.
If rates continue the National AIDS Trust says that by 2010 there
will be 100,000 people living with HIV in the UK.
The report also reveals worrying findings among young people with
1 in 10 (11 per cent) new diagnoses last year among 16 to 24 years
old.
PinkNews.co.uk
|
|
African Women Slam Abuse of Females With HIV/AIDS
February 4, 2008
Ouagadougou - Hundreds of sub-Saharan Africans rallied Monday in
Burkina Faso against the abuse of women infected with HIV/AIDS.
"There is no doubt that lots of human rights violations
characterise the (HIV/AIDS) pandemic," said Bernice Heloo,
president of the Society for Women and AIDS in Africa (SWAA).
"Women are the ones who most severely bear brunt of human rights
abuse, have been prone to violences and other atrocities related
to their gender and seropositive status.
"Many women have been driven from their marital homes, stripped of
their hard-earned possessions and separated from their children
and people they love," she told a conference attended by Burkina
Faso Prime Minister Tertius Zongo.
She urged the international community to lend their technical and
financial support to "strengthen the battle against gender
inequality in Africa, a key factor in the spread of the pandemic
and to contribute to the promotion of human rights for people
living with and affected by HIV/AIDS."
Around 500 women from some 30 sub-Saharan countries are taking
part in the four-day meeting debating violence against women and
HIV/AIDS, their rights and access to treatment.
Although sub-Saharan Africa is home to just over 10 percent of the
world's population, it is the most ravaged by HIV, carrying more
than 60 percent of all people living with the virus that causes
AIDS.
The conference has been organised by SWAA and its branch in
Burkina Faso with the help of UNAIDS, the Burkina Faso government
and a host of anti-AIDS non-governmental organisations.
AFP
|
|
Egypt: Stop Criminalizing HIV
February 5, 2008
New York - A series of arrests in Cairo sparked by one man's
admission to police that he was HIV-positive endangers public
health as well as human rights, Human Rights Watch said today.
Human Rights Watch called on Egyptian authorities to overturn the
convictions of four men for the "habitual practice of debauchery,"
and to free four others who are held pending trial. The government
should end arbitrary arrests based on HIV status and take steps to
end prejudice and misinformation about HIV/AIDS.
"These shocking arrests and trials embody both ignorance and
injustice," said Scott Long, director of the Lesbian, Gay,
Bisexual, and Transgender Rights Program at Human Rights Watch.
"Egypt threatens not just its international reputation but its own
population if it responds to the HIV/AIDS epidemic with prison
terms instead of prevention and care."
The arrests began in October 2007, when police stopped two men
having an altercation on a street in central Cairo. When one of
them told the officers that he was HIV-positive, police
immediately took them both to the Morality Police office and
opened an investigation against them for homosexual conduct. The
two men told human rights defenders that they were slapped and
beaten for refusing to sign statements the police wrote for them.
They spent four days in the Morality Police office handcuffed to
an iron desk, sleeping on the floor. Police later subjected the
two men to forensic anal examinations designed to "prove" that
they had engaged in homosexual conduct.
Human Rights Watch has documented that such examinations to detect
"evidence" of homosexuality are not only medically spurious but
constitute torture.
Police then arrested two more men because their photographs or
telephone numbers were found on the first two detainees.
Authorities subjected all to HIV tests without their consent. All
four are still in detention, pending prosecutors' decision on
whether to bring charges of homosexual conduct. The first two
arrestees, who reportedly tested HIV-positive, are being held in a
Cairo hospital, handcuffed to their beds and only unchained for an
hour each day.
Meanwhile, police apparently placed the apartment where one of the
men had lived under surveillance. On November 20, two days after a
new tenant had assumed the lease, police raided the apartment and
detained four other men.
According to the arrest report, the men were fully dressed and
were not engaging in any illegal acts at the time of the arrests.
However, all were charged with homosexual conduct, apparently
solely on the basis that they were found in a dwelling formerly
occupied by one of the earlier detainees.
People who have spoken to the four men since their arrest told
Human Rights Watch that a non-commissioned officer in the police
station beat one detainee on the head several times. Police
allegedly forced the four men to stand in a painful position for
three hours with their arms lifted in the air. They were provided
no food, drink, or blankets during their first four days of
detention. Authorities also tested these men for HIV without their
consent. One of the men reportedly said that the prosecutor, when
informing him that he had tested positive for HIV, told him:
"People like you should be burnt alive. You do not deserve to
live."
A Cairo court convicted these four men on January 13, 2008 under
Article 9(c) of Law 10/1961, which criminalizes the "habitual
practice of debauchery [fujur] a term used to penalize consensual
homosexual conduct in Egyptian law. According to defense
attorneys, the prosecution based their case only on coerced and
repudiated statements taken from the men, and neither called
witnesses nor produced other evidence to counter the men's pleas
of not guilty. On February 2, 2008, a Cairo appeals court upheld
their one-year prison sentence. One of them is held in a Cairo
hospital, chained to his bed 23 hours a day.
"These cases show Egyptian police acting on the dangerous belief
that HIV is not a condition to be treated but a crime to be
punished," said Long. "HIV tests forcibly taken without consent,
ill-treatment in detention, trials driven by prejudice, and
convictions without evidence all violate international law."
In private letters sent to the Egyptian Public Prosecutor,
Counselor Abdel Meguid Mahmoud Abdel Meguid, on November 29, 2007
and on January 8, 2008, Human Rights Watch expressed its grave
concern about the arrests and their consequences for Egypt's
efforts against HIV/AIDS.
Human Rights Watch urged authorities to drop the charges, end the
practice of chaining detainees in hospital, and ensure that the
men receive the highest available standard of medical care for any
serious health conditions. It also urged Egypt to undertake
training for all criminal-justice officials on medical facts and
international human rights standards in relation to HIV, and to
halt immediately all testing of detainees without their consent.
Criminalizing consensual, adult homosexual conduct violates human
rights protections to individual privacy and personal autonomy
under international law. The apparent use of Article 9(c) in these
cases to detain people on the basis of their declared HIV status,
and to test them without their consent for HIV infection, also
violates those international protections, and the right to bodily
autonomy.
International human rights law clearly affirms that prisoners and
detainees retain the absolute right to protection against torture
and cruel, inhuman, or degrading treatment or punishment and enjoy
the right to the highest attainable standard of health, as
guaranteed in Article 12 of the International Covenant on
Economic, Social and Cultural Rights, to which Egypt has been
party since 1982.
Human Rights Watch, Reuters
|
Studies
& Treatment News
|
Scientists Find New Receptor for HIV
February 11, 2008
San Francisco - Government scientists have discovered a new way
that HIV attacks human cells, an advance that could provide fresh
avenues for the development of additional therapies to stop AIDS,
they reported on Sunday.
The discovery is the identification of a new human receptor for
HIV The receptor helps guide the virus to the gut after it gains
entry to the body, where it begins its relentless attack on the
immune system.
The findings were reported online Sunday in the journal Nature
Immunology by a team headed by Dr. Anthony S. Fauci, the director
of the National Institute of Allergy and Infectious Diseases.
For years, scientists have known that HIV rapidly invades the
lymph nodes and lymph tissues that are abundant throughout the
gut, or intestines. The gut becomes the prime site for replication
of HIV, and the virus then goes on to deplete the lymph tissue of
the key CD4 HIV-fighting immune cells.
That situation occurs in all HIV-infected individuals, whether
they acquired the virus through sexual intercourse, blood
transfusions, blood contamination of needles and syringes, or in
passage through the birth canal or drinking breast milk.
The findings appear to provide some, if not the main, answers to
how and why that situation occurs.
Dr. Warner C. Greene, an AIDS expert and the director of the
Gladstone Institute of Virology and Immunology here who was not
involved in the research, said the findings were "an important
advance in the field."
"They begin to shed light on the mysterious process on why the
virus preferentially grows in the gut," Dr. Greene said in an
interview.
Dr. Fauci, James Arthos, Claudia Cicala, Elena Martinelli and
their colleagues showed that a molecule, integrin alpha-4 beta-7,
which naturally directs immune cells to the gut, is also a
receptor for HIV A protein on the virus’s envelope, or outer
shell, sticks to a molecule in the receptor that is linked
specifically to the way CD4 cells home in on the gut, the
researchers said.
Binding of the virus to the integrin alpha-4 beta 7 molecule
stimulates activation of another molecule, LFA-1, which plays a
crucial role in the spread of the virus from one cell to another.
The actions ultimately lead to destruction of lymph tissue,
particularly in the gut.
Several other receptor sites for HIV are known. The most important
is the CD4 molecule on certain immune cells; the molecule’s role
as an HIV receptor was identified in 1984.
Two other important receptors, known as CCR5 and CXCR4, were
identified in 1996. CCR5 is a normal component of human cells and
acts as a doorway for the entry of HIV People who lack it because
of a genetic mutation rarely become infected even if they have
been exposed to HIV repeatedly.
"The work we did took nearly two years, and there’s little doubt
that what we have found is a new receptor," Dr. Fauci said in an
interview after giving a lecture here, adding that "we certainly
have to learn a lot more about it."
Scientists have sought to identify receptors because they offer
targets for the development of new classes of drugs.
For example, last year the Food and Drug Administration approved
for AIDS treatment a Pfizer drug, Selzentry or maraviroc, which
works by blocking CCR5.
Dr. Fauci said he hoped his team’s findings would encourage other
scientists from different disciplines to explore new ways to
attack HIV
A number of experimental drugs that block the integrin alpha-4
beta-7 receptor are being tested for the treatment of autoimmune
disorders. Dr. Fauci said such drugs should also be studied for
their potential benefit in AIDS treatment.
Organization of new trials in the next year or so could test such
drugs in animals and humans to determine their safety and
effectiveness against HIV, Dr. Fauci said.
One candidate is a drug, Tysabri or natalizumab, that is marketed
for treatment of multiple sclerosis, Dr. Fauci said. Biogen/Elan
makes Tysabri.
If trials for HIV are successful, Dr. Fauci said, the drugs could
be added to existing treatment regimens.
By Lawrence K. Altman, The New York Times
|
|
Probiotics May Ease Gut Problems In People With HIV/AIDS
February 4, 2008
Probiotic supplements may ease the suffering from diarrhoea and
nausea amongst people with HIV and AIDS, suggests a joint study by
African and Canadian researchers.
The occurrence of diarrhoea was stopped by taking the gut-friendly
bacteria among 24 people with HIV/AIDS in the sub-Saharan region
of Africa, a population where many suffer from debilitating
effects of diarrhoea, and only a few have access to antiretroviral
therapy, reports the new study.
"This is the first study to show the benefits of probiotic yogurt
on quality of life of women in Nigeria with HIV/AIDS, and suggests
that perhaps a simple fermented food can provide some relief in
the management of the AIDS epidemic in Africa," wrote lead author
Kingsley Anukam in the Journal of Clinical Gastroenterology.
The researchers, from the University of Benin, Benson Idahosa
University, and the Canadian Research and Development Centre for
Probiotics at the University of Western Ontario, recruited 24
women with HIV/AIDS aged between 18 and 44 and with clinical signs
of moderate diarrhoea, and assigned them to receive a normal or
probiotic yoghurt (100 mL) for 15 days.
"Given the track record of probiotics to alleviate diarrhoea,
conventional yogurt fermented with Lactobacillus delbruekii var
bulgaricus and Streptococcus thermophilus was supplemented with
probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14,"
explained the researchers.
The women were not receiving antiretroviral therapy or dietary
supplements, and the average CD4 T-lymphocyte count (the immune
system cells that the virus attacks) was over 200.
At the end of intervention period, Anukam and co-workers report
that the occurrence of diarrhoea, flatulence, and nausea was
resolved in all 12 subjects receiving the probiotic yoghurt,
compared to only two out of the 12 in the normal (control)
yoghurt.
Moreover, the average CD4 count remained the same in 92 per cent
(11 out of 12 people) of the subjects in the probiotic group,
while the level only remained the same in 25 per cent (three out
of 12 people) receiving the control yoghurt.
White blood cells counts of the probiotic-supplemented group were
5.8 billion cells per litre at the start, and 6.0 billion cells
per litre after 15 days. The level decreased slightly to 5.4
billion cells per litre 15 days after the supplementation period
stopped.
The study, although small and short, suggests probiotics could
play a role in improving the quality of life of people with
HIV/AIDS, particularly in areas where diarrhoea is a debilitating
condition.
A report published by the World Health Organisation in November
2005 showed that the number of people living with HIV was at its
highest ever: 40.3 million. More than 3 million people died of
AIDS-related illnesses in 2005, with more than 500,000 of these
children.
Previously, researchers have reported that probiotic supplements
(Lactobacillus rhamnosus GG) may provide added protection against
gastro-intestinal infection and diarrhoea in infants. The study,
published in the open access journal BMC Microbiology, was
conducted in animals and showed that 59 per cent of animal
subjects did not develop rotaviral diarrhoea when the probiotic
was administered before infection with rotavirus.
Source: Journal of Clinical Gastroenterology
Publihsed online ahead of print, January 2008, doi:
10.1097/MCG.0b013e31802c7465
"Yogurt Containing Probiotic Lactobacillus rhamnosus GR-1 and L.
reuteri RC-14 Helps Resolve Moderate Diarrhea and Increases CD4
Count in HIV/AIDS Patients"
Authors: Kingsley C. Anukam, E.O. Osazuwa, H.B. Osadolor, A.W.
Bruce, G. Reid
By Stephen Daniells,
http://www.foodnavigator.com
|
|
HIV Drugs Make Breast-Feeding Safer, Study Finds
February 4, 2008
Washington - A drug that helps prevent babies from catching the
AIDS virus at birth can also protect them while nursing,
researchers reported on Monday.
Babies of HIV-infected women who were given the drug nevirapine
while they breast-fed were half as likely to become infected, the
researchers told a meeting in Boston of AIDS experts.
Nevirapine is already widely used to protect babies at birth. A
single dose given to the mother as she goes into labor and to the
baby at birth cuts transmission by 47 percent.
But babies continue to become infected after birth, via their
mothers' breast milk, which can carry the virus. In many
developing countries breast-feeding is the only option.
Dr. Brooks Jackson of Johns Hopkins University in Baltimore and
colleagues in Ethiopia, India and Uganda wanted to see if they
could safely continue giving the drug to babies for as long as six
weeks.
They gave 2,000 new babies either nevirapine or a vitamin solution
between 2001 and 2007.
"At 6 months of age, the risk of postnatal HIV infection or death
in infants who received the six-week regimen was almost one-third
less than the risk for infants given only a single dose," Johns
Hopkins said in a statement.
The World Health Organization estimates that 150,000 infants are
infected with the AIDS through breast-feeding each year. The fatal
and incurable virus infects 33 million people globally.
Nevirapine is sold under the brand name Viramune by privately held
Boehringer Ingelheim.
By Maggie Fox, editing by Will Dunham and Cynthia Osterman,
Reuters
|
|
Diabetes Study Partially Halted After Deaths
February 7, 2008
For decades, researchers believed that if people with diabetes
lowered their blood sugar to normal levels, they would no longer
be at high risk of dying from heart disease. But a major federal
study of more than 10,000 middle-aged and older people with Type 2
diabetes has found that lowering blood sugar actually increased
their risk of death, researchers reported Wednesday.
The researchers announced that they were abruptly halting that
part of the study, whose surprising results call into question how
the disease, which affects 21 million Americans, should be
managed.
The study’s investigators emphasized that patients should still
consult with their doctors before considering changing their
medications.
Among the study participants who were randomly assigned to get
their blood sugar levels to nearly normal, there were 54 more
deaths than in the group whose levels were less rigidly
controlled. The patients were in the study for an average of four
years when investigators called a halt to the intensive blood
sugar lowering and put all of them on the less intense regimen.
The results do not mean blood sugar is meaningless. Lowered blood
sugar can protect against kidney disease, blindness and
amputations, but the findings inject an element of uncertainty
into what has been dogma — that the lower the blood sugar the
better and that lowering blood sugar levels to normal saves lives.
Medical experts were stunned.
"It’s confusing and disturbing that this happened," said Dr. James
Dove, president of the American College of Cardiology. "For 50
years, we’ve talked about getting blood sugar very low. Everything
in the literature would suggest this is the right thing to do," he
added.
Dr. Irl Hirsch, a diabetes researcher at the University of
Washington, said the study’s results would be hard to explain to
some patients who have spent years and made an enormous effort,
through diet and medication, getting and keeping their blood sugar
down. They will not want to relax their vigilance, he said.
"It will be similar to what many women felt when they heard the
news about estrogen," Dr. Hirsch said. "Telling these patients to
get their blood sugar up will be very difficult."
Dr. Hirsch added that organizations like the American Diabetes
Association would be in a quandary. Its guidelines call for blood
sugar targets as close to normal as possible.
And some insurance companies pay doctors extra if their diabetic
patients get their levels very low.
The low-blood sugar hypothesis was so entrenched that when the
National Heart, Lung and Blood Institute and the National
Institute of Diabetes and Digestive and Kidney Diseases proposed
the study in the 1990s, they explained that it would be ethical.
Even though most people assumed that lower blood sugar was better,
no one had rigorously tested the idea. So the study would ask if
very low blood sugar levels in people with Type 2 diabetes — the
form that affects 95 percent of people with the disease — would
protect against heart disease and save lives.
Some said that the study, even if ethical, would be impossible.
They doubted that participants — whose average age was 62, who had
had diabetes for about 10 years, who had higher than average blood
sugar levels, and who also had heart disease or had other
conditions, like high blood pressure and high cholesterol, that
placed them at additional risk of heart disease — would ever
achieve such low blood sugar levels.
Study patients were randomly assigned to one of three types of
treatments: one comparing intensity of blood sugar control;
another comparing intensity of cholesterol control; and the third
comparing intensity of blood pressure control. The cholesterol and
blood pressure parts of the study are continuing.
Dr. John Buse, the vice-chairman of the study’s steering committee
and the president of medicine and science at the American Diabetes
Association, described what was required to get blood sugar levels
low, as measured by a protein, hemoglobin A1C, which was supposed
to be at 6 percent or less.
"Many were taking four or five shots of insulin a day," he said.
"Some were using insulin pumps. Some were monitoring their blood
sugar seven or eight times a day."
They also took pills to lower their blood sugar, in addition to
the pills they took for other medical conditions and to lower
their blood pressure and cholesterol. They also came to a medical
clinic every two months and had frequent telephone conversations
with clinic staff.
Those assigned to the less stringent blood sugar control, an A1C
level of 7.0 to 7.9 percent, had an easier time of it. They
measured their blood sugar once or twice a day, went to the clinic
every four months and took fewer drugs or lower doses.
So it was quite a surprise when the patients who had worked so
hard to get their blood sugar low had a significantly higher death
rate, the study investigators said.
The researchers asked whether there were any drugs or drug
combinations that might have been to blame. They found none, said
Dr. Denise G. Simons-Morton, a project officer for the study at
the National Heart, Lung and Blood Institute. Even the drug
Avandia, suspected of increasing the risk of heart attacks in
diabetes, did not appear to contribute to the increased death
rate.
Nor was there an unusual cause of death in the intensively treated
group, Dr. Simons-Morton said. Most of the deaths in both groups
were from heart attacks, she added.
For now, the reasons for the higher death rate are up for
speculation. Clearly, people without diabetes are different from
people who have diabetes and get their blood sugar low.
It might be that patients suffered unintended consequences from
taking so many drugs, which might interact in unexpected ways,
said Dr. Steven E. Nissen, chairman of the department of
cardiovascular medicine at the Cleveland Clinic.
Or it may be that participants reduced their blood sugar too fast,
Dr. Hirsch said. Years ago, researchers discovered that lowering
blood sugar very quickly in diabetes could actually worsen blood
vessel disease in the eyes, he said. But reducing levels more
slowly protected those blood vessels.
And there are troubling questions about what the study means for
people who are younger and who do not have cardiovascular disease.
Should they forgo the low blood sugar targets?
No one knows.
Other medical experts say that they will be discussing and
debating the results for some time.
"It is a great study and very well run," Dr. Dove said. "And it
certainly had the right principles behind it."
But maybe, he said, "there may be some scientific principles that
don’t hold water in a diabetic population."
By Gina Kolata, The New York Times
|
|
News from the Fifteenth Conference on Retroviruses and
Opportunistic Infections in Boston
a. Circumcising HIV Positive Men May Increase HIV
Infections in Female Partners, But Fewer STIs Seen
b. Abacavir, Didanosine Linked to Increased Heart Attack Risk
c. Vicriviroc Shows Well in Treatment-Experienced Patients
d. Atazanavir in Treatment-Naïve Patients
e. Treatment Interruptions
f. Another New CCR5 Inhibitor – SCH532706
g. HIV Treatment and Infectiousness
h. Lactobacillus Supplementation Could Help Reduce Vaginal HIV
i. Start Treatment At A CD4 Cell Count Of 500 To Reduce Risk Of
Serious Non-HIV-Related Illnesses?
j. Drug Level Monitoring
k. Vaccine Failure
l. Once- vs. Twice-Daily Kaletra Tablets: Similar Safety and
Potency
m. Sexual Reinfection With HCV Following Treatment
n. Anticipated 'Slam Dunk' AIDS Treatment Fails
o. People Receiving TB Treatment No More Likely to Die Than
Others Who Start ARVs
p. Researchers Use Technique to Identify, Generate Molecules for
Microbicide Research, Development
q. Benefits To Starting Immediate Treatment When A Patient Has
An Opportunistic Infection
r. Biomarkers May Explain Risk of Treatment Interruptions
s. Research Points to the Prospect of a Once-Monthly Anti-HIV
Drug
t. GeoVax Labs, Inc.'s Promising HIV/AIDS Vaccine Trial Data
Presented at Retrovirus Conference
u. Effectiveness of Second-Line Therapy
v. Lymphomas
w. Treatment to Prevent Mother-To-Child Transmission
x. Children Infected With HIV from Pre-Chewed Food
y. Herpes and HIV Transmission
z. Gene Therapy Offers AIDS Hope
a. Circumcising HIV Positive Men May Increase HIV Infections in
Female Partners, But Fewer STIs Seen
February 3, 2008
There was a trend towards higher HIV incidence in the wives of
HIV positive men who were circumcised compared with wives of men
left uncircumcised, in the latest prevention study conducted in
Rakai province, Uganda, investigators revealed at a press
conference on the opening day of the Fifteenth Conference on
Retroviruses and Opportunistic Infections in Boston.
In 2006, a randomised trial of circumcision in Rakai reported
that circumcision led to an almost 50% reduction in a man’s risk
of acquiring HIV through heterosexual sex. The impact of male
circumcision on transmission of HIV to the female partner
remains unknown, and the study reported today set out to examine
the effects.
In the Gates Foundation-funded study, 1015 HIV positive men were
randomised either to immediate circumcision or circumcision
delayed by two years. Of these 770 were married and were asked
to invite their wives into the study; 566 wives enrolled of whom
245 (43%) were HIV-negative and therefore in a serodiscordant
relationship.
The annual HIV incidence rate in the wives of the men who were
circumcised was 14.4% over two years of follow-up compared with
9.1% in women whose partners remained uncircumcised. This result
may be due to chance as it was not statistically significant,
but was described as "unexpected and somewhat disappointing" by
lead investigator Maria Wawer of Johns Hopkins University,
Baltimore. It was not due to behavioural disinhibition; condom
use was the same in both arms.
Wawer said that these results were an additional challenge to
the rolling-out of mass circumcision programmes in Africa, which
are expected following the positive results from three
randomised controlled trials of circumcision in HIV negative
men, one of them conducted within the Rakai community.
She said: "It is inevitable that some HIV positive men will seek
circumcision. It is the only HIV prevention modality that leaves
a mark, and no one wants to be the only guy in the village who
is uncircumcised if it becomes regarded as a mark of HIV."
If the increased incidence in the partners of circumcised
HIV-positive men is real and not due to chance, it may largely
have been due to men resuming sex before their circumcision
wound was certified as having healed, Wawer added. Five out of
18 wives of men who resumed sex more than five days prior to
certified wound healing (28.8%) became HIV-positive themselves.
In contrast six out of 63 wives of men who resumed sex no
earlier than five days prior to certified wound healing were
infected (9.5%) and this was statistically equivalent to six out
of 68 wives of men who remained uncircumcised (8.8%).
After six months, HIV incidence declined to 5.7% a year in
partners of circumcised men and 4.1% in wives of uncircumcised
men, which was also not statistically significant.
The results may be partly due to HIV-positive men tending to
heal more slowly from circumcision than HIV negative men.
Seventy-one per cent of HIV positive men had healed completely
by 30 days after circumcision, compared with 83.2% of HIV
negative men.
Wawer said: "It is imperative people don’t resume sex in the
post-operative period, and because of this slightly longer
healing time we are saying don’t resume sex until six to eight
weeks after the operation."
She added that even in the RCT in HIV negative men, the benefit
from circumcision did not start to appear until more than six
months after the operation.
Effect Of Circumcision On Stis
There was better news from this and another study of the effect
of circumcision on sexually transmitted infections (STIs). In
the Rakai study, the circumcised HIV-positive men had a third
less genital ulcer disease (GUD) than those who remained
uncircumcised (10.1% versus 15.8%) and this was statistically
significant (p = 0.002). However rates of all STIs and of
bacterial vaginosis were the same in wives of circumcised and
uncircumcised men.
Another study presented by Aaron Tobian of the same team
investigated the effect of circumcision on the acquisition of
genital herpes (HSV-2) in HIV-negative men, and on the incidence
of GUD, bacterial vaginosis and trichomonas in their wives.
There was a 25% reduction in HSV-2 acquisition in the
circumcised men, and a 25% reduction in GUD, a 20% reduction in
bacterial vaginosis, and a 50% reduction in trichomonas in their
wives. Severe bacterial vaginosis fell by 60% (two per cent in
wives of circumcised men versus 6.5% in wives of uncircumcised).
All these results were statistically significant.
Among 62 men who became HIV-positive during the trial, 38 (61%)
either had HSV-2 before the trial (47%) or seroconverted
simultaneously to HIV and HSV-2 (14%).
"All the STIs observed are cofactors of HIV," Tobian commented.
"These effects may influence the positive effect of circumcision
on HIV acquisition."
References
Wawer M et al. Trial of circumcision in HIV+ men in Rakai,
Uganda: effects in HIV+ men and women partners. Fifteenth
Conference on Retroviruses and Opportunistic Infections, Boston.
Abstract 33LB. 2008.
Tobian A et al. Trial of male circumcision: prevention of HSV-2
in men and vaginal infections in female partners, Rakai, Uganda.
Fifteenth Conference on Retroviruses and Opportunistic
Infections, Boston. Abstract 28LB. 2008.
By Gus Cairns,
www.aidsmap.com
b. Abacavir, Didanosine Linked to Increased Heart Attack Risk
February 4, 2008
Abacavir—the active drug in Ziagen and a component of Epzicom
and Trizivir—may double the risk of a heart attack in
HIV-positive people currently using the drug, according to data
presented today at the 15th Conference on Retroviruses and
Opportunistic Infections (CROI) in Boston. The latest results
from the international Data Collection on Adverse events of
Anti-HIV Drugs (D:A:D) study also found an increased heart
attack risk associated with current use of didanosine (Videx EC)
but not other drugs in the nucleoside reverse transcriptase
inhibitor (NRTI) class, including zidovudine (Retrovir) and
stavudine (Zerit).
While most research has focused on the role of protease
inhibitors and the risk of cardiovascular disease, little data
have been generated regarding the potential association between
NRTIs—which are almost always used in HIV drug combinations—and
heart attacks. Zidovudine and stavudine are two NRTIs that have
been linked to higher lipid levels and insulin resistance, two
risk factors for heart disease. However, there hasn’t been any
research showing that these two agents actually increase the
risk of a heart attack.
Hypothesizing that stavudine and zidovudine do increase this
risk, the D:A:D investigators examined their suspicions by
turning to the D:A:D cohort of more than 33,000 HIV-positive
patients who have been followed over the past seven years at
clinics based in Europe, Australia and North America. To ensure
balanced reporting, the D:A:D researchers also looked at the
heart attack risk among those who have used, or are currently
taking, the NRTIs abacavir, didanosine, and lamivudine
(Epivir)—none of which have been tied to problems known to
increase the risk of cardiovascular disease.
Surprising the researchers, an increased risk of a heart attack
was documented only in patients currently receiving abacavir and
didanosine. Abacavir use was associated with a 90 percent
increased risk of experiencing a heart attack. Didanosine use
was associated with a 49 percent increased risk of a heart
attack.
Additional analysis suggested that the increased risk with these
two drugs could be confirmed only in people currently using
abacavir or didanosine. An increased risk was not found among
past users of abacavir or didanosine, regardless of how long
they were on treatment with either NRTI, provided that they had
been discontinued at least six months previously. According to
the study authors, this finding suggests that the potential
cardiovascular effects of abacavir and didanosine are reversible
if the drugs are stopped.
Neither past nor present use of stavudine or zidovudine
increased the risk of a heart attack.
A position statement released by D:A:D study organizers,
published on its website to coincide with the presentation of
the data at CROI, suggests that these results need to be
interpreted carefully and stresses that the effect of abacavir
and didanosine was most pronounced in patients with a high
underlying cardiovascular risk due to other factors.
"In people who start abacavir or [didanosine] with a low risk
based on other factors," the authors of the position statement
write, referring to those who are young, do not smoke, have no
diabetes or high blood pressure, and normal cholesterol levels,
"increasing the low risk by 90 percent still results in a low
absolute risk of having a heart attack. However, in someone who
starts off with a high risk of a heart attack based on other
factors"—such as a cigarette smoker, who has a 2- to 3-fold
greater risk of a heart attack, compared with the 1.90-fold
increase associated with abacavir treatment—"increasing this
existing high risk by 90 percent means that the additional
effect from abacavir or [didanosine] will be more important."
The D:A:D investigators did not offer a potential explanation
for these "surprising and unexpected" findings. Additional
research will be needed to explore the link between heart
attacks and the use of abacavir or didanosine.
The authors of position statement also note that patients
receiving abacavir or didanosine should consult with their
health care providers to discuss whether a modification of their
current drug regimen is appropriate.
By Tim Horn,
http://www.poz.com
c. Vicriviroc Shows Well in Treatment-Experienced Patients
February 4, 2008
Forty-eight weeks of therapy with vicriviroc, notably a 30 mg
once-daily dose of the drug combined with a Norvir (ritonavir)
booster, leads to greater viral load reductions compared with
placebo among HIV-positive patients with limited treatment
options due to drug resistance. These new data, from a clinical
trial involving Schering-Plough’s experimental CCR5 inhibitor,
were reported today at the 15th Conference on Retroviruses and
Opportunistic Infections (CROI) in Boston.
After HIV binds to the CD4 protein on T cells, the virus must
then latch onto another receptor on the cell's surface, either
CCR5 or CXCR4. Vicriviroc, like Pfizer’s approved twice-daily
entry inhibitor Selzentry (maraviroc), prevents HIV from
entering CD4 cells that carry the CCR5 receptor. Both drugs are
largely ineffective against virus that uses, or is tropic for,
the CXCR4 receptor.
The 116 patients enrolled in Schering-Plough’s Phase II
VICTOR-E1 study had tried and failed drug regimens involving all
three classes of oral HIV drugs and had viral loads of at least
1,000 copies while on their previous treatment regimen. The
patients all had CCR5-tropic virus upon study entry, confirmed
using Monogram Bioscience’s Trofile assay.
Study volunteers were randomized to once-daily vicriviroc—either
20 mg or 30 mg—with a low-dose Norvir booster, or placebo, all
in combinations with an optimized background regimen (OBR)
containing at least three approved HIV drugs.
The 48-week results from VICTOR-E1 were reported at CROI by
Barry Zingman, MD, of Montefiore Medical Center in the Bronx,
New York.
After almost a year of treatment, 14 percent of the patients had
viral loads below 50 copies in the placebo group, compared with
56 percent in the 30 mg vicriviroc group and 52 percent in the
20 mg vicriviroc group. Compared with those in the placebo
group, the percentages of patients with undetectable viral loads
were statistically significant in both vicriviroc groups.
While patients who entered VICTOR-E1 with high viral loads were
less likely to respond favorably to vicriviroc-based treatment,
those who received the 30 mg dose of the drug had the best
chance of sustained treatment response. Among those who entered
the study with viral loads of 100,000 or higher, 33 percent in
the 30 mg vicriviroc group, compared with 17 percent in the 20
mg group and 10 percent in the placebo group, had undetectable
viral loads after 48 weeks.
As for patients who entered the study with viral loads below
100,000 copies, 33 percent in the placebo group, compared with
67 and 68 percent in the 30 mg and 20 mg vicriviroc groups
respectively, had viral loads below 50 copies after 48
weeks.
Given that CCR5 inhibitors target a cellular receptor instead of
a viral enzyme, drug resistance is thought be much less of a
problem with vicriviroc. However, patients’ viruses can switch
from CCR5-tropic to CXCR4-tropic while using a CCR5 inhibitor.
This was documented in 9 percent of the placebo recipients in
VICTOR-E1, compared with 23 percent in the 30 mg vicriviroc
group and 10 percent in the 20 mg vicriviroc group.
Virologic failures—having a viral load that failed to go
undetectable or rebounded during the study—were documented in 40
percent of the placebo recipients, compared with 18 percent in
the 30 mg vicriviroc group and 8 percent in 20 mg vicriviroc
group.
In summary, Norvir-boosted vicriviroc plus OBR is associated
with significant long-term virologic control in
treatment-experienced patients. Given the more favorable
treatment response using the 30 mg dose of the drug—along with
additional data presented by Dr. Zingman showing that the 30 mg
dose was more likely to achieve therapeutic blood levels than
the 20 mg dose—the higher once-daily dose of vicriviroc should
be explored more closely in Phase III studies of the drug.
By Tim Horn,
http://www.poz.com
d. Atazanavir in Treatment-Naïve Patients
February 5, 2008
Atazanavir (Reyataz) is not recommended for first-line anti-HIV
therapy in current UK HIV treatment guidelines.
Kaletra(lopinavir/ritonavir) is recommended by these guidelines
for treatment-naïve patients and is a popular choice amongst
patients who opt to start treatment with a protease inhibitor.
Atazanavir has some advantages, in particular it is only taken
once-daily and seems less likely to cause diarrhoea than other
protease inhibitors.
A study presented to CROI showed that atazanavir boosted by
ritonavir could be a safe and effective option for people
starting anti-HIV treatment. It showed that patients who started
antiretroviral therapy with a combination of drugs that included
once-daily atazanavir were just as likely as patients who
started treatment with a regimen containing twice-daily Kaletra
to have an undetectable viral load (below 50 copies/ml) after a
year.
CD4 cell counts increased equally in patients taking the two
drugs.
Fewer patients taking atazanavir experienced nausea or diarrhoea
and blood fats were also lower in atazanavir-treated patients.
But atazanavir can cause a side-effect called
hyperbilirubinaemia that involves a non-dangerous yellowing of
the skin and whites of the eyes.
www.aidsmap.com
e. Treatment Interruptions
February 5, 2008
Two years ago the SMART treatment interruption study was stopped
early when it was found that patients who took CD4-guided
treatment breaks were more likely to develop HIV-related
illnesses and some serious non-HIV-related illnesses than
individuals who took continuous HIV treatment.
Further results from the SMART study presented to this year’s
CROI showed that treatment interruptions could have long-term
consequences.
These showed that in the 18 months after the study was
concluded, rates of HIV-related opportunistic infections and
death from any cause remained higher in patients who took
treatment interruptions than in patients who took their HIV
therapy continuously.
The investigators suggest that "antiretroviral therapy
interruption is associated with long-term consequences beyond
the period of treatment interruption."
www.aidsmap.com
f. Another New CCR5 Inhibitor – SCH532706
February 5, 2008
Another CCR5 inhibitor being investigated in clinical trials in
SCH532706. The potency of this drug is boosted by ritonavir.
The drug is in the early phases of development, but results from
twelve HIV-positive patients (four of whom were taking anti-HIV
treatment for the first time) show that ten days of treatment
with SCH532706/ritonavir significantly lowered viral load and
increased CD4 cell count.
The most common side-effect was an upset stomach, but one person
did develop inflammation of the sac around the heart
(pericarditis), which the researchers think was "possibly
related" to the drug.
www.aidsmap.com
g. HIV Treatment and Infectiousness
February 5, 2008
Last week Swiss HIV experts issued a statement saying that
individuals taking anti-HIV therapy who have an undetectable
viral load in their blood for six months or more and who do not
have a sexually transmitted infection should not be considered
able to transmit HIV to their sexual partners.
It was a controversial statement, but it has helped focus
attention on the ability of antiretroviral therapy to reduce HIV
transmissions.
Now a study conducted in Uganda and presented to CROI suggests
that anti-HIV treatment combined with safer sex education and
adherence support could cut HIV transmissions by 91%.
The study lasted three years. There were 62 couples in the study
where one partner was HIV-positive and the other HIV-negative.
Only one partner became infected with HIV during the study and
this infection happened soon after anti-HIV treatment was
started.
It is thought the single infection happened because the infected
woman’s husband had a slow response to anti-HIV therapy and took
six months to achieve an undetectable viral load.
www.aidsmap.com
h. Lactobacillus Supplementation Could Help Reduce Vaginal HIV
February 5, 2008
The composition of the vaginal microflora affects the viral load
within the vaginal secretions of HIV-positive women, according
to a late-breaking abstract presented on Monday at the Fifteenth
Conference on Retroviruses and Opportunistic Infections in
Boston.
Lead author Jane Hitti of the University of Washington at
Seattle said that about 50% of the women studied at any time had
hydrogen peroxide-producing (H2O2+) Lactobacillus, which is
found in the microflora of a healthy vagina. The change in
vaginal microflora seen in bacterial vaginosis, and especially
the loss of H2O2+ Lactobacillus, is associated with increased
risk of HIV infection.
There is a dynamic relationship between the Lactobacillus and
the bacteria that cause bacterial vaginosis, Hitti said.
BV-associated bacteria appear to actively increase HIV
replication while the H2O2+-producing bacteria inhibit it.
In a prospective, observational cohort study, which assessed the
effect over time of H2O2+ Lactobacillus colonisation on HIV
viral load in vaginal secretions, women whose bacterial
microflora switched from those cause BV to those Lactobacillus
experienced a 0.7 log (fivefold) drop in the HIV viral load in
vaginal secretions (cervico-vaginal lavage or CVL). Conversely,
a switch from Lactobacillus to BV bacteria signalled a 0.5 log
(threefold) increase in CVL viral load.
For the study, 57 HIV-1-infected women from Seattle and from
Rochester, NY were recruited and followed every three to four
months for a median of six visits per woman (range one to 15
visits, with four in the first year and three a year
thereafter). At each visit, plasma and CVL viral loads were
determined, and cultures to identify H2O2+ Lactobacillus and BV
bacteria were performed and the women were also tested for
gonorrhoea, trichomoniasis and chlamydia.
At the start of the study, 31 (54%) women were on antiretroviral
therapy and 22 (39%) had an undetectable viral load (<30
copies/mL). Lactobacillus was present in 32 women, 18% of whom
had clinical signs of BV; it was absent in 25 women, 47% of whom
had clinical BV.
During the study, blood viral load was detectable at 64% of
visits and CVL viral load was detectable (>1500 copies/mL) at
17% of visits; CVL viral load was highly correlated with plasma
viral load (p<0.001), but not antiretroviral therapy
(p<0.78).
The presence of H2O2+-producing bacteria was in itself
associated with a threefold reduction in CVL viral load (p =
<0.01) and BV bacteria with a 60% increase (p= 0.015).
Trichomonas was also associated with a threefold increase in
viral load but because infections were less common, this was not
statistically significant.
The data yielded 270 visit pairs suitable for analysis of
changes in microflora. Colonisation by H2O2+ Lactobacillus was
dynamic over time. While almost half, 121 (47%), of visit pairs
had stable colonisation between visits, 39 (15%) visit pairs
reported the appearance of the bacterium between visits. A
similar number, 36 (14%) visit pairs, reported the loss of the
bacterium between visits, and 62 (24%) showed no evidence of
colonisation at either visit.
As described above, appearance of the H2O2+ Lactobacillus
between visits was associated with a 0.7 log10 decrease in CVL
viral load (p = 0.015), and loss of the bacterium resulted in a
0.5 log10 increase in CVL viral load (p = 0.029) when compared
with stable colonisation. All results were adjusted for changes
in plasma viral load and antiretroviral therapy status, but not
for herpes (HSV-2) status or shedding – one limitation of the
study.
When clinical BV was present, women were treated for it, but
Hitti commented that treating BV got rid of the associated
bacteria but was not necessarily associated with the
reappearance of Lactobacillus.
Hitti commented that these changes in CVL viral load associated
with changes in vaginal microflora might one day inform positive
prevention strategies for HIV-positive women. She said "If a
probiotic replacement proves to be effective this could be an
important strategy."
However, she added, although there had been a few studies to see
if supplementation with Lactobacillus formulations could
re-establish stable colonisation in HIV-negative women, she was
unaware of any studies done in HIV-positive women, and hoped
funding would be forthcoming for one.
Asked to comment on women possibly trying over-the-counter
supplements, Hitti commented that the vaginal Lactobacillus was
"a cousin" of those found in yoghurt and derived supplements and
would not necessarily have the same H2O2+-secreting properties
or effect on HIV.
Reference
Hitti J et al. Protective Effect of Vaginal Lactobacillus on
Genital HIV-1 RNA Concentrations: Longitudinal Data from a US
Cohort Study. 15th Conference on Retroviruses and Opportunistic
Infections, Boston, abstract 27LB, 2008.
By Gus Cairns & Virginia Differding,
www.aidsmap.com
i. Start Treatment at a CD4 Cell Count Of 500 to Reduce Risk of
Serious Non-HIV-Related Illnesses?
February 6, 2008
Treatment guidelines (such as those in Europe and the US) are
now recommending that HIV treatment should be started when an
individual’s CD4 cell count is around 350 cells/mm3. Previous
guidelines recommended the initiation of treatment when a
patient’s CD4 cell count was around 200 cells/mm3.
These were changed when studies showed that patients who started
treatment at higher CD4 cell counts had much better long-term
improvements in their immune system. Furthermore, results from
the SMART treatment interruption study showed that a low CD4
cell count increased the risk of serious non HIV-related
illness, such as some cancers as well as heart, kidney and liver
disease.
But could treatment guidelines soon be recommending starting
treatment at an even higher CD4 cell count? There is evidence
from the UK that patients with a CD4 cell count of 350 cells/mm3
have more HIV-related illnesses and a greater risk of death than
patients with a CD4 cell count of 500 cells/mm3.
Prof Andrew Phillips of London’s Royal Free Hospital analysed
results from a number of studies showing that HIV may have an
important role in some serious non-HIV-related illnesses. He
suggested that the earlier use of antiretroviral therapy could
reduce the risk of these illnesses.
"We need to be looking at whether antiretroviral therapy should
be initiated earlier in patients with CD4 cell counts above 500
[cells/mm3]", Prof Phillips told CROI delegates.
www.aidsmap.com
j. Drug Level Monitoring
February 6, 2008
Increasing doses of protease inhibitors after therapeutic drug
monitoring does not improve the overall chance of
treatment-experienced patients achieving and maintaining an
undetectable viral load, according to a US study presented to
CROI.
Although this strategy had no benefit for Caucasian patients, it
did have a modest effect on the viral load of black and Hispanic
individuals.
The study involved 194 patients who had experience of at least
one protease inhibitor, but who still had a viral load above
1000 copies/ml.
Four weeks after changing treatment to a new protease
inhibitor-based combination they had levels of medicines in
their blood monitored. Patients with low blood concentrations of
drugs were randomised to either continue with their current
protease inhibitor dose or to have the dose of their protease
inhibitor increased.
But 20 weeks later, viral load was more or less the same in both
groups of patients.
When the researchers looked at the results in more detail, they
found that increasing the dose of protease inhibitors had better
results in black and Hispanic patients than in white patients.
The amount of resistance a patient had to protease inhibitors
also seemed to be important. Those with least protease inhibitor
resistance had the biggest reductions in viral load after the
doses of their new protease inhibitor were increased.
www.aidsmap.com
k. Vaccine Failure
February 6, 2008
Last year, the study looking at Merck’s potential HIV vaccine,
ad5, was stopped when it was shown that people who received the
vaccine had a higher risk of infection with HIV than those who
received the placebo.
A detailed analysis of the trial’s results was presented to
CROI:
http://www.aidsmap.com/en/news/E30B88ED-2A6C-44D3-9AF6-61DB62FD9D0D.asp
This showed that the increased risk of HIV was almost entirely
located in uncircumcised men who had unprotected insertive anal
sex.
Researchers think that the vaccine may have interfered with the
men's natural immune responses to HIV. This might have been
related to the men’s immunity to adenovirus, a common cold-type
virus, that was used as the vaccine’s "delivery vehicle."
www.aidsmap.com
l. Once- vs. Twice-Daily Kaletra Tablets: Similar Safety and
Potency
February 5, 2008
Once- and twice-daily doses of Kaletra (lopinavir/ritonavir)
tablets have similar tolerability and comparable efficacy,
according to 48-week results from a clinical trial reported
yesterday at the 15th Conference on Retroviruses and
Opportunistic Infections (CROI).
In the United States, Kaletra has been approved by the U.S. Food
and Drug Administration (FDA) for use once or twice daily in
people starting HIV treatment for the first time, with a total
daily dose of 800 mg lopinavir and 200 mg ritonavir using either
schedule. Only twice-daily dosing is approved for
treatment-experienced patients.
Despite approval from the FDA, there have been lingering
concerns about the safety and effectiveness of once-daily
Kaletra therapy in treatment-naive patients.
Initial studies comparing once- and twice-daily Kaletra involved
the original capsule formulation of the drug. While the
effectiveness of once-daily Kaletra was found to be comparable
to twice-daily dosing, diarrhea rates were higher in the
once-daily group.
Abbott eventually brought a tablet version of the drug to market
that, according to a study of patient surveys in October 2006,
was less likely to cause diarrhea.
Questions soon emerged about the effectiveness of the drug taken
once daily, notably in patients starting therapy for the first
time with high viral loads (100,000 copies or higher). This was
explored, in some detail, in two presentations at the 11th
European AIDS Conference this past October in Madrid.
While Kaletra remains a "preferred" protease inhibitor for
HIV-positive individuals starting therapy for the first time,
the U.S. Department of Health and Human Service’s most recent
version of its federal treatment guidelines—updated January 29,
2008—suggests that twice-daily Kaletra may be a more suitable
dosing option for those with high pre-treatment viral
loads.
To better understand the safety and efficacy of once- and
twice-daily dosing of the Kaletra tablets—and to formally
compare Kaletra tablets with Kaletra capsules—Abbott funded an
international study involving 600 HIV-positive patients
beginning antiretroviral therapy for the first time. For the
first eight weeks of the study, the patients were divided into
four groups: one group took twice-daily Kaletra tablets, a
second group took twice-daily Kaletra capsules, a third group
took once-daily Kalera tablets, and a fourth group took
once-daily Kaletra capsules. From there, patients in the
once-daily Kaletra groups were maintained on once-daily Kaletra
tablets; patients in the twice-daily Kaletra groups continued
the study using twice-daily Kaletra tablets.
All patients received standard doses of Viread (tenofovir) and
Emtriva (emtricitabine) throughout the study.
According to Joe Gathe, MD, a Houston-based researcher who
presented the results of Study M05-730 at CROI, approximately 78
percent of the study volunteers were male and roughly 75 percent
were white. Average viral loads at the start of the study were
almost 100,000 copies, with an even distribution of patients
with viral loads below and above this level. CD4 counts at
baseline averaged 215 cells.
In the comparison between Kaletra capsules and tablets, no
significant differences in the side effects of the two
formulations were reported—rates of mild-to-severe diarrhea were
similar in all four groups of patients during the first eight
weeks of the study.
As for the the comparison between once- and twice-daily Kaletra
tablets—the predominant focus of the CROI presentation—77
percent in the once-daily Kaletra group and 76 percent in the
twice-daily Kaletra group had viral loads below 50 copies after
48 weeks. As this difference was so slight, the once-daily
results were said to be "non-inferior" to the twice-daily
findings—comparable efficacy between the two groups.
There were no statistically significant differences in treatment
responses between the two groups among those who entered with
viral loads above or below 100,000. Similarly, there were no
statistically significant differences in the virologic response
to once- or twice-daily Kaletra treatment among those who
entered with CD4 counts below 50 cells, between 50 and 200
cells, or above 200 cells.
Seven patients had resistance testing available—10 in the
once-daily group and seven in the twice-daily group—through week
48. No resistance to lopinavir or tenofovir was documented.
Three—two in the once-daily group and one in the twice-daily
group—had HIV that developed the M184V mutation, conferring
high-level resistance to Emtriva.
As for side effects, rates of moderate or severe diarrhea were
similar between the two groups, occurring in 17 percent of those
in the once-daily Kaletra group and 15 percent of those in the
twice-daily Kaletra group. Moderate or severe nausea occurred in
7 and 5 percent and vomiting in 3 and 4 percent, respectively.
Moderate or severe lab abnormalities, such as liver enzyme
increases, cholesterol gains, triglyceride elevations and
decreases in creatinine clearance, generally occurred in less
than 5 percent of the patients enrolled in the clinical trial,
with no statistically significant differences between the two
study groups.
The only statistically significant difference between the two
groups was the change in total cholesterol after 48 weeks of
treatment: a gain of 29 mg/dL in the once-daily Kaletra group,
compared with a 34.5 mg/dL gain in the twice-daily Kaletra
group.
Finally, Dr. Gathe ad his colleagues explained that study
volunteers who switched from Kaletra capsules to tablets after
the first eight weeks of the study, "overwhelmingly preferred"
the tablets to the capsules.
The researchers concluded, "This study is the largest study to
date comparing once-daily and twice-daily dosing of Kaletra, and
the first utilizing the tablet formulation. Overall, during the
first 48 weeks of treatment, no clinically important differences
were identified in the safety and tolerability of once-daily vs.
twice-daily dosing of Kaletra."
By Tim Horn,
http://www.aidsmeds.com
m. Sexual Reinfection with HCV Following Treatment
February 4, 2008
Reinfection with hepatitis C virus (HCV), after undergoing
successful treatment for the liver infection, can occur
following a subsequent sexual exposure to the virus, according
new data involving eight gay and bisexual HIV-positive men
reported today at the 15th Conference on Retroviruses and
Opportunistic Infections (CROI) in Boston.
Evidence confirming that HCV can be spread sexually continues to
mount, with the vast majority of reports involving men who have
sex with men. There’s also no shortage of research confirming
that individuals who successfully undergo a year of toxic
antiviral treatment for HCV are not always in the clear—some
patients see a relapse of their infection, whereas others can be
reinfected with another strain of HCV via the same transmission
route responsible for their first infection with the virus.
Rachel Jones, MD, of the Chelsea and Westminster NHS Foundation
Trust in London, and her colleagues set out to determine whether
infection relapse or reinfection was to blame for a resurgence
of detectable HCV viral loads in a small group of HIV-positive
gay and bisexual men, several months after being successfully
treated for the hepatitis C.
The researchers first queried databases at both Chelsea and
Westminster and Royal Free Hospitals to find individuals with
detectable HCV viral loads following a sustained virologic
response (SVR) to initial hepatitis C treatment. An SVR is
typically defined as an undetectable HCV viral load for at least
six months after spontaneously clearing the infection or
following completion of standard treatment: pegylated interferon
plus ribavirin.
Once the individuals were found, the genes from their HCV
samples—collected during the first and second period of
detectable virus—were compared. Sexually transmitted infection
diagnoses during the HCV SVR—a potential marker of sexual
behavior that may have facilitated a transmission of a second
hepatitis C virus—were also recorded in the database.
Of the 211 HIV/HCV-coinfected individuals in the data, 16 had at
least two episodes of HCV infection, with the second episode
typically diagnosed following a routine liver function test. All
were men who have sex with men. They had been infected with HIV
for approximately four years and, on average, were 38 years old
when they were diagnosed with the initial HCV infection. The
average length of the SVR, between periods of detectable HCV,
was 20 months.
Dr. Jones’s group was able to collect paired samples from eight
of the individuals. Genetic analysis revealed two individuals
with viruses that were similar enough to indicate late relapse.
In the remaining six, there were enough differences between the
paired viruses to indicate reinfection with different strains.
All but two individuals had at least one sexually transmitted
infection during their SVR periods, syphilis being the most
common.
In conclusion, Dr. Jones and her colleagues suggest that six of
the men were likely reinfected with HCV after successfully
completing treatment for an initial infection. These
reinfections, the authors said, were likely related to ongoing
high-risk sexual activity. In the other two patients, the
strains were closely related, likely indicative of a late
relapse of the infection—or possibly reinfection from a common
source.
By Tim Horn,
http://www.aidsmeds.com
n. Anticipated 'Slam Dunk' AIDS Treatment Fails
February 5, 2008
Boston -- A once-promising experiment to see whether treating
genital herpes with a common drug could dramatically reduce
susceptibility to HIV infection has found no protection
whatsoever - a shocking setback for researchers hoping to find a
pill that would slow the spread of the AIDS epidemic.
Results of the long-awaited study, which included gay men in San
Francisco, Seattle, New York and Peru, as well as women in
Africa, were released in Boston Monday at the 15th annual
Conference on Retroviruses and Opportunistic Infections, the
premier annual scientific meeting of AIDS researchers.
Nearly 20 years of various studies on herpes had shown that
herpes infection nearly tripled the risk of contracting HIV. The
assumption was simple: Use acyclovir, a proven anti-herpes drug,
to knock down that infection, and the odds of avoiding HIV would
dramatically improve - by at least 50 percent, on par with the
prevention benefit now attributed to male circumcision.
Results of the experiment were shielded from researchers and
subjects alike until the study was completed, but when
statisticians tabulated their data, the answer was certain.
Those who took acyclovir to suppress their herpes infections
acquired HIV infections at exactly the same rate as those who
took a placebo.
"This was a huge setback for HIV prevention," said Dr. Sharon
Hillier, a researcher at the Magee-Womens Research Institute at
the University of Pittsburgh.
Scientists had a lot of reasons to think that the results of
this study could be as exciting as the findings in 2005 and 2006
that adult male circumcision - the surgical removal of the
foreskin - reduced by as much as 60 percent the risk that those
men would contract HIV.
"Many people thought this was going to be a slam dunk," said Dr.
Connie Celum, the University of Washington professor who led the
study since it was approved in 2004.
"It was definitely disappointing, but it was also very clear,"
she said of the result.
Her experiment was often compared to the circumcision trials,
because the researchers were aiming for the same fence: to prove
that the intervention could reduce HIV infections by half.
Circumcision is believed to lower HIV risk because the foreskin
is rich in infection-fighting white blood cells that are targets
particularly favored by the AIDS virus. Similarly, there have
been studies showing that the lesions created by herpes
infection are portals of entry for HIV.
And as was the case with circumcision, this carefully monitored
trial was based on years of prior studies that strongly
suggested the idea would work.
"This was the study everyone thought they had already had the
answer to," said Dr. Eric Goosby, chief executive of the Pangaea
Global AIDS Foundation in San Francisco. "So much for that."
Now, the long and difficult task is to find out why the approach
did not work, and what might be done to come up with different
outcome.
The theory that immediately jumped to the top of the list of
possibilities is that suppressing herpes was not enough.
Although acyclovir is a very effective treatment for herpes
simplex 2, it does not eradicate it, and many of those who take
acyclovir will continue to have occasional flareups of genital
ulcers.
One puzzle facing scientists is that the acyclovir treatments
reduced herpes lesions by different percentages in different
groups: 32 percent among African women, 41 percent among gay men
in Peru, and 50 percent among gay men in the United States. But
prior studies had shown the drug was capable of 80 percent
suppression.
"This is the real crux of the problem," Celum said. "We need to
try to understand it."
A possible solution would be to increase the dosage of the
anti-herpes drug beyond the two tablets a day used in this
experiment. However, Celum said that other experiments have
shown no real improvement in herpes suppression with
higher-than-standard doses.
Dr. Anthony Fauci, director of the National Institute for
Allergy and Infectious Diseases, said the results were
disappointing. "I would have thought we would have seen at least
some effect," he said.
Despite the experiment's failure, Celum said that her team will
continue its work on another major study testing whether the
anti-herpes drug might block certain HIV infections involving
couples. This one will treat herpes in HIV-infected men or women
whose sexual partner is HIV-negative, and may or may not have
herpes. The experiment will attempt to show that by taking
acyclovir, the HIV-infected person will be less infectious, and
far less likely to transmit the AIDS virus to his or her
partner. The study is winding up in June, and results should be
ready in about a year.
Dr. Kevin De Cock, director of the department of HIV/AIDS at the
World Health Organization, said he was disappointed by the
results of the study, but not entirely surprised. "What we
really need," he said, "is a herpes vaccine."
Such a vaccine has eluded drugmakers for decades, despite the
clear need in societies that could afford to pay for one.
Although a herpes vaccine tested by Chiron Corp. of Emeryville
failed in clinical studies, the National Institutes of Health is
sponsoring trials of other candidates.
By Sabin Russell, San Francisco Chronicle
o. People Receiving TB Treatment No More Likely to Die Than
Others Who Start ARVs
February 6, 2008
People receiving treatment for pulmonary TB are no more likely
to die if they start antiretroviral treatment than their
counterparts without TB, according to findings from South Africa
presented today at the Fifteenth Conference on Retroviruses and
Opportunistic Infections in Boston. The only exception to this
finding is malnourished people with TB who start ART less than
30 days after starting TB treatment.
The study was carried out because there are conflicting data
from resource-limited settings regarding the impact of active
tuberculosis on the risk of death in HIV-positive patients
starting antiretroviral therapy.
To gain a better understanding of this issue investigators from
the University of North Caroline School of Public Health and the
Themba Lethu Clinic in Johannesburg performed a retrospective
study. They wanted to see if patients with active tuberculosis
when they started anti-HIV treatment had an increased risk of
death or loss to follow-up (for reasons other than transferring
care to another HIV treatment centre) than tuberculosis-free
patients.
The study ran between April 2004 and August 2007. Of the 7519
clinic patients who started antiretroviral therapy during this
period, 1202 (16%) had active tuberculosis and were included in
the investigators’ analysis. Of these patients, 284 received
tuberculosis treatment for 30 days or less before anti-HIV
treatment was started.
HIV disease status was worse in patients with active
tuberculosis than the patients who did not have tuberculosis at
the time antiretroviral therapy was started. CD4 cell counts (77
cells/mm3 vs. 113 cells/mm3, p < 0.001) were lower in
patients with tuberculosis, as was haemoglobin (79% of
tuberculosis patients having low haemoglobin compared to 56% of
other patients, p < 0.001). Patients with tuberculosis were
also significantly more likely than the non-tuberculosis
patients to start anti-HIV therapy with a regimen that included
efavirenz (95% vs. 78%).
Overall there was no difference in the risk of death or loss to
follow-up for patients with or without active tuberculosis in
the twelve months after anti-HIV therapy was initiated.
Multivariate analysis showed that there was a significantly
elevated risk of death only in the group of patients at greatest
risk of HIV disease progression: those with a CD4 cell count
below 50 cells/mm3 and those with a low body mass index (BMI
below 18.5m2).
This analysis showed that patients receiving fewer than 30 days
of tuberculosis therapy who had a low body mass index were
significantly more likely to die or be lost to follow-up than
non-tuberculosis patients with a low body mass index (incidence
rate ratio [IRR] = 5.6; 95% CI, 2.46 – 12.74). Furthermore,
patients who received over 30 days of therapy for active
tuberculosis before initiating antiretroviral therapy and who
had a very low CD4 cell count were significantly more likely to
have a poor outcome than tuberculosis-free patients starting
anti-HIV treatment with a CD4 cell count below 50 cells/mm3 (IRR
= 4.26; 95% CI, 2.42 – 7.47).
"Our results suggest that individuals receiving tuberculosis
treatment are not at increased risk of death after
[antiretroviral therapy] initiation", comment the investigators.
They add, however, "individuals with additional risk factors,
such as low body mass index and low CD4 counts may have
substantially increased risks."
Reference
Westreich D et al. The influence of TB on early mortality in the
Themba Lethu clinical cohort, Johannesburg, South Africa.
Fifteenth Conference on Retroviruses and Opportunistic
Infections, Boston. Abstract 145, 2008.
By Michael Carter,
www.aidsmap.com
p. Researchers Use Technique to Identify, Generate Molecules for
Microbicide Research, Development
February 6, 2008
Researchers from Case Western Reserve University in Ohio have
used a technique called phage display to identify and generate
molecules for use in microbicide research and development,
according to a study presented Monday at the 15th Conference on
Retroviruses and Opportunistic Infections in Boston, the
Cleveland Plain Dealer reports (McEnery, Cleveland Plain Dealer,
2/5). Microbicides include a range of products -- such as gels,
films and sponges -- that could help prevent the sexual
transmission of HIV and other infections (Kaiser Daily HIV/AIDS
Report, 12/20/07).
For the study, Michael Lederman, director of Case's Center for
AIDS Research, and colleagues used phage display to generate
molecules that act like an experimental drug -- called
PSC-RANTES -- that was found to block the vaginal transmission
of SIV in monkeys. The drug also could be used in the
development of a microbicide for use among humans, according to
the Plain Dealer. PSC-RANTES closes molecular receptors that HIV
uses to replicate, but its production is "incredibly expensive,"
according to the Plain Dealer.
Using phage display, the researchers identified and generated
three molecules that prevented HIV from entering cells. Because
the molecules occur naturally in the body, they can be produced
at a lower cost compared with PSC-RANTES, the Plain Dealer
reports. The study also found that in addition to being
antiviral agents, two of the molecules did not appear to produce
any serious immunological reactions. The researchers will
present the findings at a microbicide conference in India later
this month and hope to attract funding for further research
(Cleveland Plain Dealer, 2/5).
http://www.kaisernetwork.org
q. Benefits To Starting Immediate Treatment When A Patient Has
An Opportunistic Infection
February 7, 2008
Patients who are ill because of HIV-related opportunistic
infections are generally recommended to start anti-HIV therapy
as soon as possible.
Introducing anti-HIV therapy whilst a patient is still receiving
treatment for their opportunistic infection reduces the risk of
risk of death or further disease progression, compared to
waiting until treatment for the opportunistic infection is
completed, and doesn’t increase the risk of side-effects, a
study presented to CROI shows.
US researchers compared two groups of patients who were ill
because of HIV and who were not taking antiretroviral therapy.
One group of patients started anti-HIV therapy and treatment for
their opportunistic infection at the same time. The other group
of patients waited to start anti-HIV treatment until they’d
completed therapy for their infection.
The study didn’t include patients with tuberculosis.
Overall, just under half the patients taking immediate or
deferred anti-HIV treatment experienced no further HIV disease
progression and managed to get their HIV viral load to
undetectable levels.
But further analysis of the results showed that patients who
deferred anti-HIV treatment were about 50% more likely to
develop another AIDS-defining illness or die than those taking
immediate treatment. And CD4 cell counts increased at a slower
rate in those waiting to start treatment.
Starting treatment immediately didn’t have any additional risks.
There were no difference in rates of adherence between the two
groups of patients. Nor was there any difference in the risk of
developing an immune reconstitution inflammatory syndrome once
treatment was started.
www.aidsmap.com
r. Biomarkers May Explain Risk of Treatment Interruptions
January 7, 2008
Patients who take treatment interruptions have indicators of
increased inflammation as well as dysfunction in the lining of
the blood vessels. This could explain the increased risk of
illness and death due to diseases not usually associated with
HIV, such as heart, kidney and liver disease, seen in the SMART
study.
Researchers looked at the results of the SMART and STACCATO
treatment interruption studies. They told CROI that HIV
replication during structured treatment breaks affected key
biomakers that indicate inflammation, increased blood clotting
and endothelial dysfunction – reduced flexibility in the lining
of blood vessels, an early sign of heart disease.
www.aidsmap.com
s. Research Points to the Prospect of a Once-Monthly Anti-HIV
Drug
January 7, 2008
Once-daily anti-HIV treatment was considered a breakthrough, but
researchers are now developing an anti-HIV drug that might need
to be taken just once a month.
An experimental NNRTI called rilpivirine has been formulated
with nanoparticles. Results in animals suggest that once-monthly
injections could be enough to treat HIV.
Researchers are trying to find other drugs that could be
formulated in a similar way. This could mean that potent,
multi-drug anti-HIV treatment could be developed that is
injected monthly.
This technology could also be used for HIV prevention to provide
long-lasting pre-exposure prophylaxis or a as a microbicide.
www.aidsmap.com
t. GeoVax Labs, Inc.'s Promising HIV/AIDS Vaccine Trial Data
Presented at Retrovirus Conference
Planning for Phase 2 is Underway
February 7, 2008
Atlanta - Dr. Harriet Robinson, lead scientist and co-founder of
GeoVax Labs, Inc., (OTC Bulletin Board: GOVX - News) an
Atlanta-based biotechnology company developing HIV/AIDS
vaccines, co-presented successful Phase I trial results at the
15th Conference on Retroviruses and Opportunistic Infections
(CROI), February 5 in Boston.
Dr. Robinson, a co-founder of the GeoVax HIV-1 AIDS vaccine
technology, jointly presented the findings, entitled "GeoVax
Clade B DNA/MVA HIV/AIDS Vaccine is Well Tolerated and
Immunogenic when Administered to Healthy Seronegative Adults,"
with Dr. Bernard Moss of the U.S. National Institutes of Allergy
and Infectious Diseases and co-founder of the GeoVax vaccine.
In the presentation, Robinson reported that a dose escalation
study showed that a 1/10th dose and an anticipated normal dose
of the GeoVax vaccine both elicit anti-viral CD4 and anti-viral
CD8 T cells. However, the fuller dose elicited a higher number
of antibody responders.
For the normal dose, 77 percent of the participants had
responding CD4 T cells; 42 percent had responding CD8 T cells,
and 88 percent experienced an anti-Env antibody response. The
vaccine was also found to be safe.
Based on the excellent immune response rates and the GeoVax
HIV/AIDS vaccine's ability to protect non human primates against
AIDS development in pre-clinical challenge models, planning of a
large Phase 2 trial is underway and tentatively scheduled for a
mid-2008 start.
As recently announced, due to the significant advances by
GeoVax's HIV/AIDS vaccine development program, Dr. Robinson is
joining the GeoVax management full time on February 15, 2008, as
Vice President of Research and Development. By focusing her
efforts exclusively at GeoVax, Dr. Robinson intends to speed up
the vaccine development and human trial evaluation program
required to meet FDA regulatory requirements and future vaccine
commercialization efforts.
Dr. Robinson stated, "Our AIDS vaccine efforts are rapidly
moving forward to a new and exciting level and include plans for
initiating Phase 2 human trials in 2008. It's important to me to
be able to work full time with the GeoVax team to learn
absolutely everything we can from our phase 2 trials so that we
appropriately set the stage for phase 3 efficacy trials. I
believe in the GeoVax vaccine and want to carry it forward as
rapidly and as effectively as possible for worldwide use for the
prevention of AIDS."
The HIV Vaccine Trials Network (HVTN) in Seattle is testing
GeoVax's HIV/AIDS vaccines. HVTN funded and supported by the
National Institutes of Health (NIH), is the largest worldwide
clinical trials program dedicated to the development and testing
of HIV/AIDS vaccines. The National Institute of Allergy and
Infectious Diseases of the U.S. National Institute of Health
funded pre-clinical work enabling the development of the
clinical evaluation of GeoVax's DNA and MVA vaccines.
The NIH recently provided additional support to GeoVax's vaccine
development program in the form of a $15 million IPCAVD grant
awarded in October 2007.
PRNewswire-FirstCall,
http://biz.yahoo.com
u. Effectiveness of Second-Line Therapy
February 8, 2008
Better drugs and improved care means that second-line anti-HIV
therapy now has a good chance of offering long-term control of
viral load.
Researchers pooled information obtained from 22 cohort studies
from around the world.
This analysis showed that soon after potent antiretroviral
therapy became available in 1996 – 97 the incidence of
virological failure during second-line therapy was 114 cases per
100 person years. This fell to 42 cases per 100 person years in
2000 – 2001. By 2004 – 2005, the rate of second-line treatment
failure had fallen to just 15 cases per 100 person years.
But despite these advances in controlling viral load with
second-line anti-HIV therapy, the researchers found that the
risk of death for patients whose second-line treatment failed
remained unaltered between 1996 – 2005.
www.aidsmap.com
v. Lymphomas
January 8, 2008
A study has looked at the risk factors for lymphomas in patients
taking anti-HIV treatment.
German researchers found two main risk factors: having a
detectable viral load, which increased the risk of Burkitt or
Burkitt-like lymphomas; and having a CD4 cell count below 200
cells/mm3 increased the risk of non-Hodgkin’s lymphoma.
It is therefore very important that patients receive treatment
with the aim of suppressing viral load to the lowest possible
levels, said the researcher who conducted the study.
www.aidsmap.com
w. Treatment to Prevent Mother-To-Child Transmission
January 8, 2008
Treating HIV-infected mothers with tenofovir and FTC
(emtricitabine) for a week after labour in addition to
single-dose nevirapine during labour is safe and helps prevent
the transmission of nevirapine-resistant virus to babies.
A study presented to CROI included 38 HIV-positive mothers in
Africa and Asia. All the women received AZT from the 28th week
of pregnancy to prevent mother-to-child transmission. During
labour they also received a single dose of nevirapine as well as
tenofovir and FTC. They then received a week of treatment with
tenofovir and FTC. Their infants received nevirapine at birth
and AZT for the first week of life.
This treatment produced big drops in the mothers’ viral load.
None of the infants were infected with drug-resistant virus.
About a quarter of the women experienced side-effects, and
adverse events were observed in a similar proportion of infants.
But it is likely that many of these were unrelated to the use of
anti-HIV drugs.
www.aidsmap.com
y. Children Infected With HIV from Pre-Chewed Food
January 8, 2007
Three children in the US have been infected with HIV after been
given pre-chewed food. The food had blood on it from the mouth
of the adult caregiver.
HIV-positive caregivers are being warned not to give pre-chewed
food to children.
In resource-limited countries pre-chewing of food is common
because of a lack of prepared baby food, so pre-chewing may pose
a greater risk where there is a high prevalence of HIV and oral
health is poor.
www.aidsmap.com
y. Herpes and HIV Transmission
January 8, 2008
Providing anti-herpes treatment to women lowers HIV viral load
in both blood and vaginal secretions, a study conducted in Peru
shows.
The study involved 20 women who were infected with both HIV and
genital herpes (HSV-2). Half the women were given the
anti-herpes drug valaciclovir to take every day, the other ten
women were given a placebo.
Results showed that valaciclovir reduced HIV viral load in both
the blood and in vaginal fluids. It also reduced the shedding of
HSV-2.
And a study conducted amongst gay men in the US showed that
HIV-positive gay men with HSV-2 were 16 times more likely to
pass on HIV to their partner if their partner did not have
genital herpes. Suppressing HSV-2 in HIV-positive men could,
therefore, reduce the risk of HIV transmission.
These studies come after trials showed that providing
anti-herpes treatment did not reduce HIV infections in men or
women.
www.aidsmap.com
z. Gene Therapy Offers AIDS Hope
February 09, 2008
Scientists believe they may have pioneered a way to make the
HIV/AIDS virus slow its reproduction, and potentially even
self-destruct.
For the first time, researchers have slowed and possibly stopped
the AIDS virus from reproducing in patients by using a gene
therapy that tricks it into destroying itself, reported wire
service MCT.
The results, announced on Wednesday, are heartening not just for
people infected with HIV but also for the field of gene therapy,
which remains highly experimental more than 20 years after
scientists figured out how to use viruses to insert therapeutic
genes into a cell's genome.
Mostly, the results are a big step forward for the biotech
start-up that is developing the novel therapy and for its
collaborators at the University of Pennsylvania.
"The buzzword in the field is viral 'fitness', meaning how well
the virus can replicate," said Gary McGarrity, executive
vice-president for scientific affairs at Virxsys Corporation, in
Gaithersburg, Maryland.
"In eight of the nine patient samples we studied, we see
diminished HIV fitness up to two years after treatment."
That raises the hope that even if medical science cannot come up
with the holy grail of AIDS research -- a vaccine to prevent HIV
infection -- patients may be able to keep HIV under control,
perhaps without relying on the toxic drug cocktails that
commuted what was once a death sentence.
"I think the Virxsys report is very important," said John Rossi,
a molecular biologist at the City of Hope in California, who is
also working on a gene therapy treatment for HIV.
"A lot of HIV patients are over 60 now and they're suffering the
consequences of these toxic drugs. This shows there are
alternatives."
The field of gene therapy has suffered years of missteps and
controversy -- notably the 1999 death of Arizona teenager Jesse
Gelsinger in an unrelated gene therapy experiment at Penn.
"I think the field is really starting to accelerate," said
physician Carl June, who leads the Penn team that is
collaborating with Virxsys. "There was so much frustration for
years. But now there are new breakthroughs."
The latest gene therapy, called VRX496, is still in early human
testing intended to demonstrate safety and determine the best
dosages.
Of the 54 patients who have been treated so far in the ongoing
clinical trial, none have experienced serious side effects, and
many have seen clinical signs of effectiveness -- their HIV
viral loads have fallen and their supply of infection fighting T
cells has grown.
A Penn patient, one of the first and sickest to be treated,
remains well more than four years later - even though
conventional cocktails of anti-retroviral drugs had stopped
working for him.
Wednesday's report, presented by Virxsys at a conference in
Boston, looked deep into the molecular level of blood samples
from nine randomly chosen patients to see whether the therapy
was hitting its target.
VRX496 capitalises on the fact that viruses are impotent on
their own but powerful inside a cell. That is the only place
they can replicate, by hijacking the host's molecular machinery.
HIV seizes control by splicing its own genes into the DNA of
infection-fighting T cells, the backbone of the immune system.
The genetic wizardry involved in outwitting HIV is complex.
First, the researchers remove T cells from an HIV patient and
insert into those cells a gene that stops the AIDS virus from
reproducing. Then, using Penn's patented technology, the T cells
are multiplied a hundredfold and put back into the patient.
The vehicle, or "vector", that is used to insert this protective
gene into the T cells is novel in itself: a disarmed version of
HIV.
The gene carries instructions that eliminate the HIV virus'
ability to wrap its DNA in an armoured shell. So when HIV
invades the T cell, it steals this new armour-making gene,
escapes from the cell - and then finds itself unable to make the
shield it needs to break into more cells.
The latest study also found that the inserted gene is a
double-whammy for HIV. The virus tries to simply delete the gene
-- its favourite mutating tactic for becoming resistant to
current drugs -- but that, too, reduces its reproductive
"fitness." (It gets "wimpy", to use Dr June's word.)
The researchers found that blood samples from the nine cases
presented yesterday were in fact loaded with the virus, most of
it having mutated into harmless forms.
"For HIV to mutate around our treatment, it has to commit
suicide," said Mr McGarrity, the Virxsys executive.
If this gene therapy becomes an approved treatment, still years
away, the estimated cost for the one-time series of infusions
would be $US130,000 ($A146,000), said Riku Rautsola, Virxsys'
chief executive. While that's a hefty sum, the lifetime cost for
conventional HIV-fighting drugs is about $US700,000 ($A785,000).
"We hope (VRX496) will become a frontline therapy once we have
proven the impact is durable," Rautsola said. "This would
clearly be better in terms of quality of life for the patients."
http://www.news.com.au/heraldsun
|
Links
of Interest
|
Death
March
February 10, 2008
Gideon Mendel/Corbis An HIV-positive mother takes her medication, Lusikisiki district, 2004.
Sizwe’s Test: A Young Man’s Journey Through Africa’s AIDS Epidemic.
By Jonny Steinberg, published by Simon and Schuster
No matter how serious a disease may be, devising a cure or treatment or ways of prevention is only half the battle. The other half can be more mysterious. Throughout the world, people who should know better eat, drink or have sex in needlessly risky ways, or ignore medical danger signs until it is too late. These, the willful ignorers, are what interest the South African journalist Jonny Steinberg about the gravest medical crisis his country has experienced: AIDS. More than one out of every eight South Africans is HIV positive, Steinberg reports; every day roughly 800 South Africans die of AIDS and more than 1,000 additional people are infected. A recent survey found that in the previous month, the average South African was more than twice as likely to have been to a funeral as to a wedding.
Pushed hard by a determined citizens’ movement, the South African government has at last begun widely distributing antiretroviral drugs. Why, Steinberg asks in "Sizwe’s Test," do so many people dying of AIDS not take them? And why do millions of South Africans at risk not even get tested for the virus?
To answer these questions, Steinberg, a Johannesburg
newspaper columnist who has written several previous
nonfiction books, focuses on Lusikisiki, a district in the
country’s Eastern Cape Province. It is one of the
overcrowded black rural slums left behind by the centuries
in which white farmers seized well over 80 percent of South
Africa’s most fertile land. Almost one out of three pregnant
women in Lusikisiki was HIV positive, but the area also had
a first-rate AIDS treatment program: well-stocked clinics
run in cooperation with the local health authorities by the
respected Médecins Sans Frontières. It seemed the perfect
place to study.
Steinberg presents the district largely through the eyes of
one man, whom he calls Sizwe Magadla. Sizwe is 30, healthy
and literate; as the owner of a small shop, he is a rare
mover and shaker in a community with high unemployment,
where most people are struggling just to get by. Reasonably
sophisticated about medicine, Sizwe knows that
antiretrovirals are the best AIDS treatment so far, and he
actually urges a sick relative to get tested. But despite
being at risk himself — he has had unprotected sex with many
women before recently settling down with one — he refuses to
take an HIV test. He becomes both Steinberg’s window onto
Lusikisiki and an object of study himself.
Steinberg unfolds the story in a leisurely, almost rambling
way, in successive layers, as he gets to know Sizwe and the
community’s complex social network. The first layer has to
do with the extreme lack of privacy. In Lusikisiki, everyone
knows exactly who’s sleeping with whom: houses are small and
packed with several generations of curious relatives, and
even when a couple try to find some space of their own,
dozens of pairs of eyes see them disappearing into the
forest together. And if you get your HIV test results at one
of the clinics, hundreds of your fellow villagers are
waiting in line behind you. If you immediately leave the
nurse’s office and go home, they know you’re HIV negative;
if you’re kept behind for an hour of counseling, they know
you’re positive.
The next layer down has to do with fear. Although he doesn’t
yet have enough money for a car, Sizwe is relatively
prosperous and worries about the envy of his fellow
villagers since he has made his money from them. Not only
that, but a rival shopkeeper with connections to a criminal
gang has his eye on Sizwe’s business. He fears any sign of
weakness or vulnerability could lose him customers or get
him robbed.
But there’s an even deeper level to people’s resistance to
testing and treatment. As with many indigenous peoples —
I’ve encountered the same belief among Indians in the Amazon
— the Xhosa people of Lusikisiki see sickness as a kind of
bewitchment, something sent to you by ancestors you have
offended or by those who wish you ill. If whites already
took so much farmland and mineral wealth, the thinking goes,
could not the very needle the white doctor or his nurses use
to draw blood be what’s spreading AIDS in the first place?
And if an enemy does attack you, what more deadly way than
with an illness that seems connected to a man’s potency and
ability to procreate? Men are anxious about these things the
world over, but nowhere more so than when, in desperate
poverty, they possess little else.
Although Steinberg writes in the first person, he largely
keeps himself out of the story until about 30 pages from the
end. And then, before returning to Sizwe again, he suddenly
shares some intimate pieces of his own life. I will not
spoil the effect of this forceful narrative twist by telling
more, except to say that it greatly helps to etch the final
layer he uncovers. This has to do with the immense power of
stigma, the ways in which we mirror the real or imagined
condemnation of others by internalizing it, and of how
easily stigma becomes entwined with sexuality.
For all its sharp insights and value, "Sizwe’s Test" has one
serious flaw. Steinberg devotes only a perfunctory few pages
to Thabo Mbeki, South Africa’s president since 1999 and
powerful deputy president for five years before that. Mbeki
long denied that the HIV virus causes AIDS, embracing a
small coterie of similarly-minded crackpot scientists and
appointing a health minister who promoted, as a cure, the
use of garlic, olive oil and various herbs. Drawing outrage
from AIDS activists everywhere, these bizarre beliefs
delayed the large-scale distribution of antiretroviral drugs
year after precious year. Hundreds of thousands of South
Africans who have died of AIDS might still be alive today if
Mbeki had repeatedly spoken out about safe sex and AIDS
testing and treatment, and had thrown the full weight of his
ruling party apparatus behind such a campaign. Several other
African leaders, most notably President Yoweri Museveni of
Uganda, have done just this and have saved countless lives
as a result. If Mbeki had been shown on TV getting an AIDS
test, I bet Sizwe would have gotten his.
To play down Mbeki’s stubborn obscurantism in a book about
AIDS in South Africa is like writing a book about Americans
and global warming while ignoring seven years of stubborn
obscurantism on that subject from the White House. It is
precisely when folk beliefs, fear and stigma attached to
serious illness are most deeply rooted, in the way Steinberg
shows so well, that forceful truth-telling by a country’s
leaders becomes most important to create a sea change in
long-established attitudes and habits. The failure of
leadership in South Africa has been a great tragedy for a
long-suffering people who deserve better.
By Adam Hochschild, The New York Times
Adam Hochschild is the author of six books; his "Mirror at
Midnight: A South African Journey" was reissued by Houghton
Mifflin last year in an updated edition.
http://blogs.poz.com/david/archives/2008/01/hot_metal_hubri.html
|
|
|